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Fatigue is a common complaint in patients with neurological disorders. Fatigue is well 
documented in disorders of the central nervous system such as multiple sclerosis and post-
stroke. Although acknowledged, fatigue in disorders of the peripheral nervous system is less 
studied and underlying pathophysiology is not understood.  It has been hypothesised that 
fatigue may relate to progressive loss of peripheral motor units or disorganised peripheral 
motor unit firing. This study aimed to explore experienced fatigue in chronic demyelinating 
disorders of the peripheral nerves and relationship with quality of life. The study also aimed 
to investigate peripheral motor unit function using a newly-developed electrophysiology 
technique, explore how this relates to self-reported experience of fatigue and development 
of muscle fatigue during exertion. 
Fatigue in patients with chronic demyelinating disorders of the peripheral nervous system 
appears to be negatively correlated with quality of life.  Patients with both acquired and 
hereditary chronic demyelinating peripheral nerve disorders have reduced number of motor 
units assessed using MUNIX technique compared to control subjects. However, no clear 
relationship is found between number of functioning peripheral motor units and fatigue 
levels experienced by patients. Depression and reduced grip strength were significant 
predictors of higher experienced fatigue levels in patients with chronic inflammatory 
demyelinating polyneuropathy. This suggests fatigue in this patient group is likely to be 
multifactorial, with physical and psychological contributors. Significant changes in MUNIX 
values were found following intravenous immunoglobulin therapy in patients with chronic 
inflammatory demyelinating polyneuropathy, highlighting a potential role as a monitoring 
tool for treatment response. 
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Fatigue is a recognised feature of a wide-range of neurological disorders1. The experience of fatigue 
usually refers to the physical or mental experience of a lack of energy or lack of motivation, although 
perhaps unsurprisingly given its inherently subjective nature, no universally agreed definition of 
fatigue exists in the scientific literature2. Approaches to the study of fatigue also vary. Exploration of 
an individual’s experience of fatigue typically utilises self-report psychometric scales to assess either 
fatigue levels or the impact of fatigue on daily functioning3. Research from the physiological 
scientific literature typically focuses on development of muscle fatigue during activity or exertion, 
expressing fatigue as a decline in the maximal force that may be generated by a muscle or muscle 
group over time4. How these separate aspects of fatigue relate, if at all, is far from clear. 
The available evidence in neurological disorders mainly involves studies exploring fatigue in the 
context of disorders of the central nervous system, including multiple sclerosis5, stroke6 and 
Parkinson’s disease7. It is only recently that fatigue has received attention in disorders of the 
peripheral nervous system. This is perhaps surprising given that fatigue has been a long-recognised 
sequelae of disorders such as Guillain-Barre syndrome (GBS), at least anecdotally, and has been 
reported subjectively by patients as one of the most disabling features of their disorder8.  
GBS is the most common acute paralysing neuropathy affecting roughly 100,000 people annually 
worldwide, with distinct subtypes including forms where loss of nerve myelin is the predominant 
pathophysiological feature and forms where axonal degeneration predominates9,10. GBS is 
characterised by immune-mediated inflammation of nerve roots and peripheral nerves; a history of 
infection by viral or bacterial or agents such as Campylobacter jejuni, or of immune-activating event, 
such as influenza A vaccination is present in some but not all cases11. GBS is typically a monophasic 
illness with peak clinical deficit seen two to four weeks following onset and around one quarter of 
patients requiring ventilatory support9,12. During the acute phase of the illness, immunomodulatory 
treatments such as intravenous immunoglobulin therapy (IVIg) and plasma exchange are proven to 
reduce disease progression and speed recovery 13,14, with a recovery period which may last for 
several months or years. A first-year mortality rate of 4.4% and persistent severe motor sequalae in 
13.9% of patients at one year or later are reported15. In addition, some reports suggest only 33% of 
patients feel subjectively fully recovered at one year16, with 37.8% needing to change employment 
during this time17. 
Nearly fifty years after GBS was first described by Guillain, Barre and Strohl18, a chronic form of 
corticosteroid responsive polyneuropathy was described by James Austin19, later termed “chronic 
inflammatory demyelinating polyneuropathy (CIDP)”. CIDP is a chronically-progressive or relapsing-
Andrew Lawley                                      Life and Health Sciences                                                170230764 
10 
 
remitting condition.  Clinical presentation typically involves weakness of proximal or distal muscles, 
which is usually symmetrical, loss of sensation and neuropathic-type pain20. Clinical presentation 
may be heterogeneous, however, with less commonly reported presentations including 
asymmetrical or intermittent weakness, ataxia or muscle fatigue21.  CIDP may present at any age, 
with cases reported from infancy to the ninth decade and median age of onset in the sixth 
decade22,23. CIDP has a prevalence of up to 9 per 100,000 of the population23 and unlike the 
monophasic course of GBS, CIDP is a chronically active disease. It has been suggested by some 
authors that these conditions form part of a spectrum24. There is substantial evidence supporting 
CIDP as an immune-mediated process from animal models, pathological studies and observed 
response to immunomodulatory therapies25. The classical pathological hallmark of CIDP is multifocal 
and segmental demyelination starting in nodal regions, with autopsy studies demonstrating 
preferential involvement of proximal segments of motor nerves25.  Despite evidence supporting an 
immune-mediated aetiology, no specific triggering infective agent or immune event have been 
identified in CIDP to date20 and autoantibodies are identified in only a minority of patients26. 
IVIg is an effective treatment in CIDP, improving disability and preventing disease relapse27. In 
relapsing CIDP response to IVIg may be biphasic, with an initial rapid response seen within days, 
followed by a “wearing-off effect”28,29 requiring repeat infusions to maintain therapeutic effect in 
around 65% of patients30. Doses should be given at the maximal interval required to maintain a 
stable clinical response31, which may vary from 2 to 6 weeks32–35, possibly reflecting interindividual-
variability in pharmacokinetics of IVIg33,36,37.  Current trials examining the role of immunosuppressant 
or immunomodulatory treatments in GBS and CIDP tend to focus on outcome measures assessing 
motor or sensory function, grip strength, standard electrophysiological parameters such as 
compound motor action potential amplitude, or disability scores13,38,39. There is growing awareness 
of residual deficits in daily and social activities and reduced quality of life outcomes, which are only 
partly explained by impairments assessed using these methods40,41. Fatigue has been identified as a 
potentially disabling symptom in immune-mediated neuropathies, which may impact quality of life 
outcomes42. However, assessment of fatigue is not currently routinely included as an outcome 
measure in studies exploring effect of treatments for immune-mediated neuropathies. 
GBS and CIDP represent the acquired end of the spectrum of demyelinating disorders of the 
peripheral nervous system.  Of the hereditary demyelinating disorder of the peripheral nervous 
system, Charcot-Marie-Tooth disease (CMT) type 1 is the most prevalent, affecting around 36 per 
100,000 of the population43. The most common subtype, CMT1A, results from duplication of the 
peripheral myelin protein 22 (PMP22) gene located on the short arm of chromosome 1743,44. In 
keeping with a hereditary condition, CMT1A typically presents in the first two decades of life45. 
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However, patients may not present with symptoms until the fifth decade of life or later43, reflecting 
a variable rate of disease progression, which has been reported amongst families46 and even 
identical twins47. Typical symptoms include distal muscle weakness, distal muscle atrophy, foot 
deformity with pes cavus and clawing of toes, loss of fine motor skills, sensory loss, balance 
disturbance due to sensory proprioceptive loss and tremor43,48. Deficits in mobility, muscle 
weakness, fatigue, pain and body image have been demonstrated to negatively impact quality of life 
in patients with CMT49. The classic pathological hallmark found on nerve biopsy is diffuse “onion-
bulb” formation, where fragments of Schwann cells appear too thin for the diameter of the axon 
they surround, reflecting chronic demyelination-remyelination50. 
There is no treatment available for CMT, although several promising compounds are being studied in 
animal and cellular models51. Outcome measures in clinical trials include the CMT neuropathy score, 
the CMT paediatric scale or measures of fine motor skills such as the nine-hole peg test45,52,53. The 
aforementioned scales contain sum scores derived from clinical assessments of motor and sensory 
function and electrophysiological studies of sensory and motor nerve function. At present, no clinical 
trials have used measures of fatigue as an outcome measure. 
Given the recognised impact of fatigue on patient quality of life, some authors have called for 
improved recognition of the importance of fatigue and inclusion of fatigue as an outcome measure 
in clinical trials for acquired and hereditary demyelinating polyneuropathies42. However, there are 
several potential obstacles, including difficulties in defining and assessing fatigue, a lack of 
understanding of the underlying pathophysiology of fatigue in this patient group and a lack of 
biomarkers for fatigue.  Lack of understanding of underlying pathophysiology presents a particular 
problem to the study of fatigue in patients with peripheral nerve disorders. No correlation is found 
between fatigue levels and functional recovery in GBS54 and fatigue does not appear to correlate 
with clinical markers of disease severity in CIDP55,56.  In fact, in a minority of patients with CIDP 
fatigue may be the main presenting symptom57. Standard electrophysiological markers used to 
assess nerve dysfunction also show no correlation with severity of experienced fatigue in patients 
with GBS58, although to date no similar explorations have been made in patients with CIDP or CMT. It 
has been hypothesised that fatigue may relate to more complex alterations in peripheral motor unit 
function, not readily assessable by standard electrophysiology studies58,59. Motor unit function index 
(MUNIX), is a recently developed technique60,61, which allows parameters related to the number of 
motor units (MUNIX) and size of motor units (MUSIX) innervating a muscle to be obtained. It has the 
advantage of being non-inferior to and technically easier to perform than currently available motor 
unit number estimation (MUNE) techniques62, and is therefore easier to incorporate into routine 
clinical practice. Application of this technique to patients with peripheral nerve disorders may allow 
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improved understanding of the relationship between fatigue and peripheral nerve dysfunction.  In 
order to understand these issues in more detail, a systematic review of the literature is conducted. 
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2. Literature review: A systematic review of fatigue in demyelinating disorders of the 
peripheral nervous system 
A systematic review of the literature was undertaken, including only English-language, primary 
research studies published in peer-reviewed journals. Randomised and non-randomised controlled 
trials, cohort studies, cross-sectional studies and case series with reference to fatigue in 
demyelinating disorders of the peripheral nervous system were selected. All age groups were 
included. Single case reports were excluded due to lack of generalisability. 
Ovid MEDLINE (1946 to February 2018) and Pubmed databases were searched on 4th February 2018, 
using the search terms ‘fatigue and neuropathy’, ‘fatigue and Charcot’, ‘fatigue and Guillain’, ‘fatigue 
and polyneuropathy’, ‘fatigue and CIDP’ and ‘fatigue and neurophysiology’, as well as their 
derivations, as keywords or text words. Reference lists from identified articles were manually 
screened. 
All relevant studies were reviewed and analysed using a data collection form adapted from the 
Cochrane Handbook for Systematic Reviews of Interventions63 (see Appendix 1). The following 
objectives were identified: 
• To address how fatigue is defined in patients with demyelinating polyneuropathies 
• To understand methods of assessing fatigue in this patient population 
• To determine the severity of fatigue and how this may impact on quality of life measures 
• To explore the underlying pathophysiology of fatigue in this patient population 
• To determine how treatment may impact fatigue for these patients 
• To identify weaknesses and gaps in the existing literature 
2.1 Findings 
2.1.1 Search results 
The search returned 123 articles, reduced to 47 following initial screening and application of 
inclusion criteria. Following review of the articles, 32 were included. A further 7 articles were 
identified on screening of reference lists, giving a total of 39 articles included in this review. These 
are summarised in Table 1. In addition, 2 relevant case reports were identified21,64. Despite not 
meeting inclusion criteria and therefore not appraised, these provide useful illustration of broader 
themes. Review of the grey literature identified 1 journal letter relating to fatigue in CIDP65 and 1 
personal account of experience of fatigue following GBS8, which are discussed and referenced where 
relevant.  
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Authors Year Study design N Demographics Fatigue assessment Key findings 













(authors own design) 
• In a small number of patients with neuromuscular disorders, 







83 GBS, 22 
CIDP, 8 
MGUS 
Age range 14-84 
years; 54 female 
Fatigue severity scale • Fatigue is a major symptom for patients with immune-
mediated polyneuropathy 
• Fatigue levels did not correlate with motor or sensory 
function, age or time since diagnosis, and severe fatigue 
could exist in the absence of weakness or sensory deficit 
• Fatigue levels higher in female than male patients 
• Fatigue severity scale has good internal consistency, 






83 GBS, 22 
CIDP, 8 
MGUS 
Age range 14-84 
years; 54 female 
Fatigue severity scale • Associations between measures of impairment, disability and 
handicap demonstrated in patients with immune-mediated 
polyneuropathy 
• Fatigue did not significantly contribute in regression models 
for handicap or disability 
Garssen, 
MPJ et al68 
2004 Case-control 
study 
16 GBS, 4 
CIDP 
Age range 22-66 
years; 14 female 
Fatigue severity scale 
and Fatigue impact 
scale 
• A graded-exercise programme improved self-reported 
fatigue, functional outcome and quality of life in in patients 
with immune-mediated polyneuropathy 
Boukhris, S 
et al57 
2005 Case series 11 CIDP Age range 39-77 
years; 0 female 
Fatigue severity scale • Fatigue may be the main presenting symptoms of CIDP 
• Anecdotal reports of fatigue improving with 
immunomodulatory treatments in some patients 
Garssen, 




13 GBS, 3 
CIDP 
Age range 26-68 
years; 10 female 
Fatigue severity scale • Fatigue experienced post-GBS not related to residual nerve 
dysfunction assessed by conventional NCS 
Garssen, 




13 GBS, 2 
CIDP 
Age range 26-68 
years; 9 female 
Fatigue severity scale • Fatigue experienced post-GBS did not appear related to 
changes in conduction velocity distribution in the median 
nerve, a measure of persisting peripheral nerve 
demyelination/suboptimal remyelination 
Garssen, 
MPJ et al54 
2006 Prospective 
survey 
100 GBS or 
variant 
Mean age 44.9 
years; 47 female 
Fatigue severity scale • Fatigue experienced post-GBS not related to disease severity 
at nadir, antecedent infection, impairment of motor or 
sensory function or time to follow-up 










74 GBS Median age 47.5 
or 52 years in 
different groups; 
40 female 
Fatigue severity scale 
and Fatigue impact 
scale 
• Amantadine was not superior to placebo in treating fatigue 
post-GBS 
• A significant placebo effect was observed, attributed to 
increased medical attention 
Garssen, 




9 GBS Age range 48-67 
years; gender NR 







• Central factors (i.e. proximal to neuromuscular junction) are 
involved in development of muscle fatigue in GBS 
• Muscle fibre hypertrophy may develop post-GBS as a 
compensatory mechanism for loss of motor units 
• Self-reported fatigue levels did not correlate with 
assessments of muscle fatigue 
Bussmann, 
JB et al72 
2007 Secondary 
analysis of data 
from Garssen et 
al 2004 
16 GBS, 4 
CIDP 
Age range 22-66 
years; 14 female 
Fatigue severity scale • Changes in fatigue seen following a graded-exercise 
programme are not related to changes in physical fitness 
• Correlation between changes following an exercise 







Age range 7-94 
years; gender NR 
Fatigue severity scale • High levels of severe fatigue lower quality-of-life scores than 
reference values in patients with immune-mediated 
polyneuropathies 
• Patients with severe fatigue more severely affected on the 
GBS-severity scale, but no correlation between fatigue level 





742 GBS Age IQR 56-74 
years; 378 female 
Fatigue severity scale • High levels of severe fatigue reported post-GBS. No 
correlation between fatigue level and time since diagnosis, 
age or gender 
• No difference in fatigue levels observed between patients 
who did and did not receive physiotherapy 








Mean age 54.6 
years; 9 female 
Fatigue severity scale • Fatigue, pain and muscle weakness are common sequalae to 
GBS, contributing to lower physical quality of life scores in 
these patients 
• Fatigue levels did not correlate with a measure of emotional 
affectivity 
Westblad, 




21 CIDP Age range 18-82 
years; 6 female 
Fatigue severity scale • Significant number of Swedish patients with CIDP experience 
severe fatigue, although lower level than reports from other 
countries 
• Patients score lower on physical domains of the SF-36 
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compared to reference values 





83 GBS, 22 
CIDP, 8 
MGUS 
Age range 14-84 
years; 54 female 
Fatigue severity scale 
and short-form 
fatigue scale 
• The fatigue severity scale does not meet expectations of the 
Rasch model due to difficulty of differentiating between 
multiple response options and one item being biased for 
patients who could walk independently 
• A new Rasch-built fatigue severity scale was developed and 




analysis of data 
from Davidson 
et al 2009 
237 GBS Median age 62 
years; 118 female 
Fatigue severity scale • Good outcome post-GBS should be defined as an F-score 
(functional scale in GBS) of 0, as patients with scores of 1 or 
more had significantly higher anxiety, depression, fatigue 





29 GBS Mean age 49 
years; 13 female 
Fatigue severity scale • Patients with poorer functional outcomes up to 10 years 
after GBS had higher fatigue levels than those with better 
functional outcomes 





24 GBS Mean age 57 
years; 9 female 
Fatigue severity scale • Severe fatigue may persist for over 20 years post-GBS 
• Fatigue levels correlate with disease severity at time of 







39 GBS Mean age 58 
years; 19 female 
Fatigue severity scale • Severe fatigue post-GBS correlates with more pronounced 
axonal loss, represented by lower MUNE values and SNAPs 
• No correlation between fatigue levels and standard NCS 
values, age and muscle weakness 









29 CMT (23 
demyCMT, 
6 axoCMT) 
Mean age 37 




• Maximum voluntary contraction, median frequency 
spectrum of SEMG and the ratio between torque and RMS of 
SEMG recorded from quadriceps muscles was significantly 
lower in CMT patients compared to controls 
• No significant difference found between endurance of 
quadriceps contraction or rate of decline in median spectral 
frequency seen between patients and controls with high 





29 CMT Mean age 37 




• A resistance strength training programme improved maximal 
force generation but not muscle fatigue in CMT 
• An increase in RMS of the SEMG signal seen early during the 
programme, interpreted as evidence for change in “neural 
mechanisms” 












Age range 18-70 
years; 11 female 
Muscle fatigue 
measured using grip 
and pinch strength 
• Hand and pinch grip strength were significantly lower in CMT 
patients than controls but the rate of strength decline during 
an intermittent fatiguing task did not differ between the two 
groups 












Age range 19-63 
years; 81 female 
Checklist of 
individual strength 
• Severe fatigue experienced by majority of patients 
• Severely fatigued patients had lower scores in all domains of 
a quality of life assessment 
• Age did not contribute to level of fatigue 
Carter, GT et 
al84 
2006 Case series 4 CMT Age range 33-65 
years; 2 female 
No formal 
assessment 
• Anecdotal reports of improvement in subjective fatigue in a 







73 CMT1 Age range 20-58 
years; 43 female 
Checklist of 
individual strength 
• Lifetime psychiatric disorders reported in 32% of patients, 
most commonly depression and phobia 






73 CMT1 Age range 20-58 
years; 43 female 
Checklist of 
individual strength 
• Level of physical activity most strongly predictive of 
experienced fatigue in CMT patients. Frequent sleep 
disturbance, pain, muscle strength and neuropsychological 
impairment (assessment of concentration) also contributed 
to experienced fatigue 
Schillings, 





73 CMT1 Age range 20-58 





• CMT patients have higher experienced fatigue levels than 
age-matched controls 
• In assessing muscle fatigue, patients have higher central 
activation failure than controls 
• Weak negative correlation between experienced and 







73 CMT1 Age range 20-58 
years; 43 female 
Checklist of 
individual strength 
• Experienced fatigue and peripheral fatigue appear to be 
unrelated in CMT patients, with central activation failure 
during a fatiguing task only weakly related to experienced 
fatigue 
El Mhandi, L 
et al89 
2008 Cohort study 8 CMT (4 
CMT1A, 4 
CMT2) 
Age range 20-44 
years; 0 female 
Visual analogue scale 




• Interval training improved self-reported fatigue but not 
muscle force production or indices of muscle fatigue 




GM et al90 
2009 Case-control 
cohort study 
18 CMT Mean age 37 
years; 8 female 
Fatigue severity 
scale. Muscle fatigue 
measured from 
quadriceps muscle 
• Self-reported fatigue levels were higher in patients and 
negatively correlated with physical endurance 
• In CMT patients, hip flexors compensate for distal weakness 





analysis of data 
Kalkman 2005 




• No difference in was observed in fatigue scores in CMT 





227 CMT Age range 18-78 
years; 130 female 
Multidimensional 
fatigue inventory-20 
• CMT patients experience higher fatigue levels than controls 
• Fatigue level correlated inversely with physical functioning 
domain of a quality of life assessment 
• Fatigue level did not correlate with poor sleep, daytime 






55 CMT1A Age range 12-18 
years; 30 female  
Checklist of 
individual strength 
• Higher rates of severe fatigue in children with CMT 
compared to healthy controls, correlating negatively with 







8 CMT1A Mean age 36 





• Patients had weaker knee extensors than controls and 
impaired neuromuscular recovery after a fatiguing task 
• No difference between patients and controls in biceps 
Ramdharry, 




25 CMT Age NR; 17 
female 
Qualitative study of 
fatigue 
• Qualitative exploration of fatigue in a cohort of CMT 
patients, exploring 4 key areas: definition, key triggers, 







6 CMT1A Mean age 40 
years; 3 female 
Fatigue severity scale • Movement-related cortical potentials were higher in 
amplitude over the prefrontal cortex in a fatiguing task in 
patients, interpreted as demonstrating higher cognitive 
effort and awareness of movement complexity 
Bachasson, 





8 CMT1A Mean age 41 
years; 5 female 
Fatigue severity scale • Assessment of feasibility of using femoral nerve magnetic 
stimulation to differentiate between peripheral and central 
muscle fatigue 
• In CMT patients, this protocol was unable to achieve 
supramaximal stimulation 






44 CMT Median age 59.5 
years; 20 female 
Fatigue severity scale • Fatigue severity correlated negatively with self-reported 
physical activity level  
• Fatigue, poor balance, weakness and pain were identified as 
common barriers to physical activity 
Andrew Lawley                                      Life and Health Sciences                                                170230764 
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Table 1 Summary of the articles identified in the systematic literature search, including details of study design, patient demographics and key findings 
(GBS=Guillain Barre Syndrome; CIDP=chronic inflammatory demyelinating polyneuropathy; CMT=Charcot-Marie-Tooth disease; MGUS=monoclonal 
gammopathy of undetermined significance; NR=not reported; QoL=quality of life; NCS=nerve conduction studies, EMG=electromyography, MUNE=motor 






2.1.2 Definition of fatigue 
Fatigue is a subjective experience, which may encompass physical exhaustion, lack of motivation, 
difficulty concentrating and muscle weakness. Whilst several studies acknowledge the complex, 
vague and subjective nature of fatigue66,74,79,80, surprisingly few offer a formal definition. Westblad et 
al75 and Kalkman et al83 define fatigue as “a sense of physical tiredness and lack of energy, distinct 
from sadness and weakness”. Highlighting difficulties in defining the perception of fatigue, 
Ramdharry et al95 undertook a detailed qualitative study exploring the experience of fatigue in 25 
patients with CMT. Interesting themes to emerge included most participants distinguishing between 
local muscle fatigue resulting from activity and refreshed by rest, and an overall sensation of energy 
depletion not necessarily refreshed by rest. Participants also stressed the abnormality of this 
sensation and how it differs from feelings of tiredness, suggesting fatigue and tiredness are separate 
phenomenological entities. Only basic demographics are provided, with details of comorbid 
conditions and medications an important omission, making it difficult to determine generalisability 
of these observations. Similar explorations of the subjective experience of fatigue have not been 
undertaken in patients with acquired forms of demyelinating polyneuropathy, although a personal 
account published by Gregory8 details a strikingly similar experience. 
Several authors71,87,94,97 distinguish between the subjective experience of fatigue, which may have 
both physical and psychological components, and physiological fatigue. Definitions of physiological 
fatigue are quoted from two review articles99,100, both generally agreeing that physiological fatigue is 
a reduction in muscle strength induced by sustained exertion. Physiological fatigue may result from 
failure to maintain muscle contraction at the level of the muscle or neuromuscular junction, termed 
peripheral fatigue87,99,100. Alternatively, suboptimal activation of the muscle by the nervous system is 
referred to as central activation failure, with its development during exercise termed central 
fatigue71,87,99,100.  Somewhat paradoxically, fatigue resulting from a disorder of the peripheral nerves 
constitutes central fatigue using this definition.  
Definitions of the subjective experience of fatigue, henceforth referred to as ‘experienced fatigue’, 
and muscle fatigue induced by prolonged exertion, henceforth referred to as ‘physiological fatigue’, 
are drawn from extensive research in the psychological and physiological sciences, respectively. 
These are not derived from direct research involving patients with disorders of the peripheral 
nerves. Therefore, the usefulness of this distinction in conceptualising fatigue in this population and 
ultimately exploring pathophysiology needs to be addressed. 
 




2.1.3 Assessment of fatigue 
Experienced fatigue is most commonly assessed using self-report scales. Dittner and colleagues3 
identify 30 fatigue assessment scales frequently used across a range of conditions, although over 
250 are reported in the literature101. The first major study55 to assess experienced fatigue in patients 
with immune-mediated neuropathy was published in 1999 using the Fatigue Severity Scale (FSS). 
This 9-item, 7-point Likert scale assesses impact and functional outcomes related to fatigue and was 
initially validated in patients with systemic lupus erythematous and multiple sclerosis102. Merkies 
and colleagues55 demonstrate good internal consistency, test-retest reliability and validity in patients 
with immune-mediated polyneuropathy when correlated with the vitality domain of the SF-
36®health survey. One hundred thirteen age- and sex-matched healthy controls also completed the 
survey. All subsequent studies have used the FSS in this patient group.  
Given the influence of this study, several important limitations of the study need to be addressed. 
Patients were recruited from a central databank, but diagnostic criteria are not defined. No 
assessment was made of comorbid physical or mental health conditions that may also cause fatigue. 
The authors somewhat arbitrarily define severe fatigue as mean score above the 95th centile in 
normal controls. Several future studies adopted this definition in defining patients as ‘severely’ and 
‘non-severely’ fatigued56,59,68,75,79. Arbitrarily dividing fatigued patients into binary categories may 
reduce ability to detect subtle trends when studying correlations of fatigue in these patients. Finally, 
the FSS is based on classical test theory. Assessment of sum scores assumes equal relevance and 
weighting of each item, when in fact the relevance of each item to a patient’s level of ability is not 
assessed. To overcome this important limitation, van Nes and colleagues used modern Rasch 
technology to develop a 7-item, 4-point linearly weighted scale for use in patients with immune-
mediated neuropathies (R-FSS), demonstrating good test-retest reliability and validity76. 
The first study to explore experienced fatigue in patients with hereditary polyneuropathy utilised the 
Checklist of Individual Strength (CIS)83. The CIS is a multidimensional 20-item, 7-point Likert scale, 
providing subscores for ‘subjective experience of fatigue’, ‘concentration’, ‘motivation’ and ‘physical 
activity’103. This scale was developed for use in patients with chronic fatigue syndrome, and has been 
demonstrated to differentiate between patients with chronic fatigue syndrome, multiple sclerosis 
and controls104. Good internal consistency and split-half reliability are demonstrated, although test-
retest reliability has not been formally assessed3. Other scales employed less frequently include the 
fatigue impact scale68,70, the abbreviated fatigue questionnaire-971,87 and the multidimensional 
fatigue inventory-2092. 




Several studies have explored physiological fatigue in patients with CMT80–82,87–90,94,97, with only one 
pilot study assessing physiological fatigue in patients with immune-mediated neuropathies71. 
Although choice of muscle group and testing protocol is highly variable between studies, all 
protocols essentially involve measurement of the deterioration in force-generating capacity of a 
muscle over time. Both continuous and intermittent muscle contraction have been used, with 
physiological fatigue expressed as the force-generating capacity of the muscle at the end of the task 
as a percentage of the initial maximal force. Only Videler and colleagues82 have assessed the test-
retest reliability of fatiguing studies, finding a modest intraclass correlation coefficient of 0.62. 
Superimposed tetanic electrical muscle stimulation has also been employed during the fatiguing 
contraction to determine ‘central activation failure’71,87, based on the principles of the ‘twitch 
interpolation technique’105. However, this technique has been criticised by some authors as painful 
and insensitive to small changes in muscle fatigue97. 
The relationship between physiological fatigue and experienced fatigue is unclear. Garssen and 
colleagues71 found no significant correlation between experienced fatigue, assessed using the FSS 
and the abbreviated fatigue questionnaire-9, and any parameter used to assess physiological fatigue. 
Schillings et al87 report a weak negative correlation between physiological fatigue and the 
abbreviated fatigue questionnaire-9. Ramdharry90 found experienced fatigue correlated with walking 
endurance but not force-generating capacity of hip flexor muscles. Kalkman88 surmises that 
‘experienced’ and ‘physiological’ represent separate and unrelated aspects of fatigue. 
These findings suggest assessment of physiological fatigue is unhelpful in understanding patients’ 
subjective experience of fatigue. However, important limitations need to be acknowledged. All 
studies exploring correlation between physiological and experienced fatigue assess maximal force 
generating capacity of proximal muscle groups (biceps brachii or hip flexors). From a methodological 
point of view this makes sense as force generation can easily be assessed in isolation. Biceps brachii 
can also easily be electrically stimulated as part of the twitch interpolation technique to assess for 
central fatigue. However, most peripheral neuropathies are ‘length-dependent’, with more severe 
involvement of the most distal nerve fibres. In addition, patients often report fatigue induced by 
low-intensity daily activity8,95. Techniques assessing development of muscle fatigue in distal muscles 
or during “real-life” tasks may be more helpful in understanding the relationship between 
physiological and experienced fatigue in this patient group. 
 
 




2.1.4 Severity of fatigue and impact on quality of life measures 
In acquired demyelinating polyneuropathy, severe fatigue is usually defined as a mean score of 5 or 
greater on the FSS, based on Merkies et al’s55 influential study. In total, 8 studies report prevalence 
of severe experienced fatigue, with values ranging from 38%59,74,75 up to 80%55. Patients also 
frequently rate fatigue as one of their most disabling symptoms55,56. Merkies et al55 found 
significantly higher levels of fatigue in their GBS group compared to CIDP, whilst Kuitwaard and 
colleagues56 found a higher rate of severe fatigue in CIDP patients.  
Quantification of experienced fatigue in CMT patients is more variable. Significantly higher fatigue 
levels are reported in comparison to healthy controls using the FSS90, the abbreviated fatigue-
questionnaire 987, the multidimensional fatigue index-2092 and the CIS83,93. Using CIS scores, 
Kalkman83 and Jagersma93 report severe fatigue in 64% of adult patients and 24% of paediatric 
patients with CMT, respectively. Using a different scale, Boentert and colleagues92 report prevalence 
of severe fatigue of 43% in adult patients. 
The use of different fatigue scales, which explore different aspects of the subjective experience of 
fatigue3, no doubt underlies some of the variation in the CMT population. However, variation is also 
seen between studies using the same scales. These differences may reflect variation based on 
sampling of patients, although other important differences in data collection need to be considered. 
Fatigue is not specific to peripheral neuropathies and may result from other physical or 
psychological disorders. When assessing CMT patients with co-morbid health conditions, Boentert 
and colleagues found severe experienced fatigue in 74%, compared to 43% of the entire cohort92. 
Only 3 of the 13 studies in this review that report prevalence of severe fatigue screened for and 
excluded co-morbid conditions which may contribute to fatigue. One further study assessed for 
medication which may cause fatigue only. Of the studies with no clearly defined exclusion criteria, 6 
conducted a postal or telephone survey, making it difficult to perform detailed clinical assessment. 
This methodology also creates a potential sampling bias, with more severely affected patients more 
motivated to respond. High non-responder rates of between 27 and 42% are reported in these 
studies56,73,74,83,93. There is also variation in how self-reported scales were completed, with some 
studies sending surveys to patients to be completed56, some providing written instructions55 and 
others requiring examiners to read surveys to patients75. The later methodology has the advantage 
of allowing patients to clarify misunderstandings. All of these factors may contribute to the variation 
in reporting of severe experienced fatigue.  




Severity of fatigue can be assessed indirectly by exploring impact of fatigue on quality of life. A single 
study70 has assessed impact of fatigue in this patient group using the Fatigue Impact Scale, 
demonstrating that results closely correlated with FSS scores. Five studies have shown a significant 
inverse correlation between FSS scores and subsections of the SF-36®health survey55,72,83,90,92. The SF-
36®health survey assesses self-reported quality of life and health perceptions and includes the 
subscales physical functioning, physical role function, emotional role function, bodily pain, general 
health, vitality, social functioning and mental health106. These scores can be converted to physical 
and mental component subscores. Studies in patients with both acquired and hereditary 
demyelinating polyneuropathies consistently find an inverse correlation between fatigue levels and 
either the physical functioning and physical role function domains of the SF-36®health survey or the 
physical domain subscale55,72,83,90,92. Relationship between fatigue levels and other domains, 
including the mental domain subscale, is inconsistent.  
Given the observed inverse correlations between fatigue severity and self-reported quality of life, it 
is perhaps surprising that the only study to evaluate links between impairment, disability and 
handicap, as defined by the World Health Organisation, found fatigue was the only impairment 
measure assessed with no significant contribution to level of disability or handicap in univariate or 
multivariate regression modelling67. The tools used to assess disability and handicap in this study 
focus predominantly on functional abilities, including arm or leg strength and ability to perform 
certain tasks, respectively. It is possible these parameters may be more affected by impairments in 
strength or sensation, whereas fatigue is more important in patient’s perception of their abilities.  
2.1.5 Pathophysiology of fatigue 
Hereditary and acquired demyelinating disorders of the peripheral nervous system share 
pathophysiological similarities although are fundamentally different disorders. It should not be 
assumed that the mechanisms underlying fatigue in these disorders are identical. The literature for 
both disorders will be considered with similarities and differences analysed. 
An early study exploring fatigue in neuromuscular disorders suggested this resulted from co-existent 
psychiatric illness rather than a direct effect of neuromuscular dysfunction66. This included a 
heterogenous group of neuromuscular disorders and only 3 patients with GBS.  The authors also 
devised their own fatigue assessment and symptom attribution scales, failing to demonstrate validity 
or reliability of either. Subsequent work involving patients with acquired and hereditary 
demyelinating polyneuropathies have largely disproved this theory. Although psychiatric illness such 
as depression and phobias exist in CMT, the prevalence of these conditions does not differ between 




severely fatigued and non-fatigued patients85. Experienced fatigue in patients with immune-
mediated neuropathies shows no correlation with measures of emotional affectivity74. In addition, 
reduced levels of motivation in a mixed group of patients with neuromuscular disorders appears 
independent of depression85. Studies exploring the relationship between fatigue and sleep 
disturbance in patients with CMT find no consistent relationship86,92. Severe fatigue also does not 
appear related to employment status in this population91. Level of physical activity is associated with 
experienced fatigue in this patient group86,98, although the relationship between these variables is 
unclear. It is possible fatigue is a sequelae of deconditioning resulting from lack of activity. 
Alternatively, high experienced fatigue levels may make patients feel less able to maintain high 
activity levels. These findings suggest experienced fatigue cannot be fully explained by factors 
related to chronic illness, such as co-morbid psychiatric illness, sleep disturbance or socio-economic 
factors. 
Long-term electrophysiological studies find weakness and persistent neurological disability are 
associated with more severe axonal loss in patients with GBS107,108. However, numerous case reports 
illustrate severe experienced fatigue may exist in the absence of significant motor or sensory 
deficits21,57,64. This observation is supported by larger cross-sectional studies, which demonstrate no 
correlation between experienced fatigue and clinical assessments of sensory or motor 
function54,55,59. In addition, no significant correlation has been found between experienced fatigue 
and standard electrophysiological parameters reflecting degree of axonal loss, including amplitude 
and area of sensory and compound motor nerve action potentials58,59. This has led to the hypothesis 
that fatigue may be related to persistent nerve demyelination or suboptimal remyelination69. Links 
between persistent fatigue in well-recovered patients with CIDP and activity-dependent conduction 
block have been suggested65. However, no correlation between experienced fatigue and sensory or 
motor nerve conduction velocities has been found58,59, including detailed studies assessing 
conduction velocity of smaller myelinated motor units69. 
Several authors have investigated physiological fatigue in CMT80,82,87,90,94,96. Although methodological 
differences make direct comparisons difficult, the majority of studies demonstrate reduced maximal 
force generating capacity of the muscle group being tested in patients compared to healthy 
controls80,82,87,90,94. However, no consistent difference between endurance of muscle contraction and 
deterioration in force generating capacity has been demonstrated. This includes protocols using 
both intermittent82 and continuous87 fatiguing muscle contractions. The only pilot study exploring 
this area in immune-mediated neuropathies found no difference between maximal force generating 
capacity or development of physiological fatigue in biceps brachii between 10 patients with well-




recovered GBS and 12 healthy controls71. This appears likely to reflect pathophysiological differences 
between patients with a subacute, acquired, immune-mediated neuropathy and a chronic, 
hereditary neuropathy.  
Similar protocols have been used to explore underlying causes of physiological fatigue in patients 
with CMT and GBS71,87. Despite differences between these conditions, both studies found higher 
central activation failure and lower peripheral fatigue in patients compared to healthy controls. As 
mentioned earlier, central activation failure refers to failure of neural drive to the muscle, whereas 
peripheral fatigue is used to refer to fatigue developing at the level of the muscle or neuromuscular 
junction itself. It is hypothesised that increased central activation failure results from fewer surviving 
peripheral motor neurons, resulting in a proportionately higher dropout rate during the fatiguing 
task. Lower peripheral fatigue is observed because of submaximal muscle activation. However, if 
physiological fatigue results from lower number of surviving motor axons, it would be expected that 
maximal muscle contraction force would be lower in patients compared to controls and the decline 
in force of muscle contraction would be more rapid. Neither of these observations is found71,87. 
Several studies utilise surface-EMG (SEMG) to assess neural drive to muscles during fatiguing 
contractions in patients with CMT and acquired demyelinating polyneuropathy71,80,81,87,94. SEMG 
signals contain summated muscle-fibre action potentials. Area and power of the rectified SEMG 
signal can be analysed using the mean absolute value or root mean square, respectively80,94, 
providing an indirect assessment of the number of motor units activating over time109. Median 
frequency of the power spectrum of the SEMG signal has been used as a measure of firing 
frequency94,109.  Differences in these parameters are reported between patients and controls, 
although no relationship between any of the SEMG parameters and experienced or physiological 
fatigue has been demonstrated, although inter-subject variability is high71,80,87,94. It could be argued 
that this finding further disproves the hypothesis that physiological fatigue is directly related to 
number of surviving peripheral motor neurons. However, there are several limitations with this 
methodology. SEMG activity does not exclusively reflect neural activity and will be affected by 
factors such as production of lactic acid during exercise110,111. This limitation may be overcome by 
recording muscle-fibre conduction velocity, which slows as intramuscular pH falls, using specialised 
multi-electrode arrays71,87,94. However, many other factors complicate recording of SEMG activity, 
including tissue inhomogeneities and effects on signal volume conduction, electrode contact, size 
and interelectrode distance and phase cancellation of action potentials at higher firing 
frequencies109,112. These factors make the relationship between SEMG signals, force and neural 
activation complex. 




Menotti and colleagues96 explore central factors influencing physiological fatigue using movement-
related cortical potentials. They identified higher activity in the prefrontal cortex and lower activity 
in the primary motor area in CMT patients than controls. Movement-related cortical evoked 
potential amplitude in the motor area is related to the level of muscle force and number of motor 
units113,114. The lower amplitude responses seen in CMT patients are attributed to lower number of 
peripheral motor units, and the authors hypothesis that higher activity in the prefrontal cortex is a 
compensatory mechanism. Given the role of the prefrontal cortex as a cognitive association area, 
the authors imply that this reflects increased cognitive effort involved in motor tasks. Compensatory 
mechanisms involving the prefrontal cortex may allow patients to maintain activity level whilst 
leading to an earlier perception of fatigue during routine motor tasks. This may account for the 
ability of patients with CMT to maintain muscle contraction despite fewer peripheral motor neurons, 
and the lack of correlation between experienced and physiological fatigue. Several other groups 
have advanced the hypothesis that experienced fatigue may result from the need to exert greater 
effort to perform normal daily activities71,72,95.  
Key to this hypothesis is a relationship between experienced fatigue and a lower number of 
functioning motor units. However, as previously described, no relationship between experienced 
fatigue and standard electrophysiological parameters of motor unit function has been 
demonstrated58,69. Following acute axonal loss in GBS or during ongoing axonal loss in CIDP or CMT, 
denervated muscle fibres may be incorporated into surviving motor units through sprouting of 
collateral motor axons. This results in a smaller number of larger motor units, disrupting the normal 
orderly recruitment of motor units, whilst maintaining the amplitude and area of CMAPs measured 
during standard electrophysiological studies. Drenthen and colleagues59 explored the relationship 
between Motor Unit Number Estimation (MUNE) and experienced fatigue in a cohort of 39 patients 
with GBS, discovering a correlation between MUNE and experienced fatigue level and that severely 
fatigued patients have larger motor unit size. MUNE is a detailed technique for assessing number of 
functioning motor units, although has several potential limitations. It is technically challenging to 
perform and requires repeated electrical stimulation, which may be poorly tolerated. Perhaps more 
importantly, the technique assumes incremental increase in compound motor action potentials seen 
with gradual increases in strength of electrical stimulation is due to recruitment of single motor 
units, which may lead to underestimation of the number of functioning motor units. Therefore, 
whilst this finding offers an insight into the pathophysiology of experienced fatigue in patients with 
immune-mediated neuropathy, this is a single study with potential technical limitations and no 
similar exploration has been made in patients with chronic polyneuropathies. 




2.1.6 Treatment of fatigue 
There is very limited information available regarding the effect of treatment on fatigue in patients 
with acquired or hereditary demyelinating polyneuropathy.  
A single case series reports improvement in FSS scores following treatment of 11 CIDP patients57. 
Treatments were heterogenous, however, with patients receiving intravenous immunoglobulin, 
corticosteroids, cyclophosphamide, or a combination of all three. This study is severely limited by 
the small sample size and the lack of a control group, meaning it cannot be discounted that observed 
improvements are due to placebo effect or natural variation in fatigue levels over time. Similarly, 
anecdotal evidence of improvement in fatigue using modafinil in CMT should be interpreted 
cautiously84. 
Inspired by the benefits of Amantadine in patients with multiple sclerosis, treatment effect of 
Amantadine in 80 patients with recovered GBS has been assessed70. This double-blind, randomised-
controlled trial is the only study of its kind in this patient group using changes in fatigue level as a 
primary endpoint. The authors used established diagnostic criteria for GBS as part of the inclusion 
criteria and carefully assessed for any comorbid conditions that may cause fatigue as part of the 
exclusion criteria. No significant impact from Amantadine was found, although there was slight 
improvement in FSS and FIS scores across both groups, which the authors attributed to the effect of 
increased medical attention. This finding demonstrates a potential placebo effect on fatigue level, 
which would need to be carefully controlled for in future studies assessing effects of treatment on 
fatigue. 
It has also been suggested that exercise can improve experienced fatigue in patients with immune-
mediated demyelinating polyneuropathy68 and CMT89,95. Garssen and colleagues68 explored benefits 
of a graded-exercise programme in a study recruiting 16 patients with GBS and 4 patients with CIDP, 
all with “severe fatigue” as assessed using the FSS. Parameters including fatigue levels (assessed 
using the FSS and FIS), depression scores, SF-36®health survey, disability and handicap scores were 
measured during a 12-week supervised exercise programme. Significant improvements were seen 
across all assessments. El Mhandi and colleagues89 report improvement in fatigue assessed on a 
visual analogue scale following a 24-week interval training exercise programme in CMT patients. 
Whilst highlighting a potentially promising area for further exploration, the lack of a control group in 
both studies means that improvements resulting from increased supervision, as seen in the 
Amantadine study, cannot be excluded. In Garssen’s study, the significance of improvement in co-
morbid depression on fatigue is also unclear. 





Fatigue appears to be a frequent and significant problem experienced in both hereditary and 
acquired demyelinating disorders of the peripheral nervous system. Patients with higher fatigue 
levels appear to have lower perceptions of their physical abilities, possibly reflecting a greater 
awareness of the difficulties of motor tasks and physical activity. Limitations of the available 
literature exist, including use of heterogenous assessment methods, somewhat arbitrary 
classification of patients’ as “severely” and “non-severely” fatigued and lack of control for comorbid 
conditions causing fatigue. Despite this, evidence from multiple sources across different patient 
populations consistently show higher self-reported fatigue levels compared to healthy control 
groups. In addition, fatigue appears distinct from tiredness, muscle weakness or co-morbid 
psychiatric conditions, suggesting it represents a distinct entity in this patient population, which is 
inversely correlated with quality of life. 
The term “fatigue” may be used to refer to patients’ subjective experience or to deterioration in 
muscle strength during exercise. Defining the aspect of fatigue being addressed is important, yet 
surprisingly few of the studies in this review offer a formal definition of fatigue. Experienced fatigue 
is typically assessed using psychometric, self-report scales. Selection of an appropriate scale may be 
difficult as numerous methods exist and many lack validity in this patient group or have limitations if 
based on classical test theory. The development of a new Rasch-built assessment tool developed 
specifically for assessment of fatigue in this patient group is an important development. The optimal 
method to assess physiological fatigue is even less clear. To date, no link between patient’s 
subjective experience of fatigue and physiological fatigue as assessed by reduction in force-
generating capacity of muscle over time has been established. Whether study of physiological 
fatigue will lead to discovery of pathophysiological mechanisms helping to understand experienced 
fatigue is far from clear. 
The pathophysiological mechanisms underlying fatigue are unclear. There may be a psychological 
component to patient’s experience of fatigue. A single medication trial demonstrates a placebo 
effect, indicating fatigue may improve in response to greater medical attention. Whilst comorbid 
depression may be another important factor, the available literature suggests fatigue experienced by 
this patient group cannot be completely attributed to comorbid psychiatric illness. Standard 
electrophysiological measures have failed to show a direct relationship between fatigue and loss of 
sensory or motor nerve axons or severity of nerve demyelination. This observation appears intuitive 
when patients may complain of little or no impairment of sensory or motor function but 
overwhelming fatigue. Interesting insights into central components of fatigue are provided by 




detailed studies of physiological fatigue and movement-related cortical evoked potentials. These 
findings suggest fatigue may develop as a result of increased cognitive effort involved in planning 
and execution of everyday tasks. Based on the findings of a single study, it has been hypothesised 
that this occurs as a compensatory strategy for loss of peripheral motor units or disordered 
peripheral motor unit function. Development of more detailed neurophysiological techniques to 
explore motor unit function may help to understand mechanisms underlying fatigue in these 
patients. Initial results from a single study in patients with GBS are encouraging. 
As may be expected given the limited understanding of causes of fatigue in patients with peripheral 
neuropathy, studies of potential treatments have focused on broad rather than targeted therapies, 
such as physical therapy, or speculative treatments which may offer benefit in unrelated conditions. 
None of the large, multi-centre studies exploring the impact of immunomodulatory treatments for 
GBS or CIDP have included fatigue assessments as outcome measures, instead focusing on 
assessments of motor or sensory function or disability scores. This may be due to a lack of 
understanding of the importance of fatigue for these patients, lack of robust methods for assessing 
fatigue, lack of biomarkers or a combination of all of these factors.  Understanding the 
pathophysiology of fatigue becomes more important to allow targeted therapies to be developed. 
2.3 Conclusion 
Fatigue is a frequent problem encountered by patients with demyelinating disorders of the 
peripheral nervous system, whether acquired or hereditary. High experienced fatigue negatively 
impacts quality of life measures. Perhaps due to a combination of factors, including lack of robust 
assessment tools or poor understanding of underlying pathophysiological mechanisms, therapeutic 
trials in these conditions rarely use fatigue as an outcome measure. This review identifies several 
gaps and limitations in the existing literature, which offer potential avenues for investigation to 
improve understanding of fatigue in patients with these conditions. 
  




3 Research aims 
 
The primary research aim of this study is  
i) To explore the relationship between experienced fatigue, physiological fatigue and 
peripheral nerve function in patients with acquired and hereditary demyelinating 
peripheral neuropathy.  
Secondary research aims of this study are: 
i) To investigate short-term changes in clinical and electrophysiological assessments 
after treatment in patients with chronic demyelinating polyneuropathy  
ii) To assess short-term changes in fatigue levels and how these correlate with clinical 
and electrophysiological assessments after treatment in patients with chronic 
demyelinating polyneuropathy 
This study will utilise the newly-developed Rasch-built fatigue severity scale to assess experienced 
fatigue. The use of a linearly-weighted scale will allow assessments of subtle trends rather than 
artificially dividing patients into “severely” and “non-severely” fatigued dichotomous categories. 
Physiological fatigue will be explored using hand-held grip dynamometry. In addition to standard 
electrophysiological assessments, more detailed exploration of motor unit function will be 
undertaken using a recently developed technique; Motor Unit Number Index (MUNIX).  
The use of linearly-weighted experienced fatigue scale will also allow exploration of correlation 
between fatigue and comorbid depression, disability level and health-related quality of life scores, 
assessed using previously validated scales.  
Finally, assessment can be performed before and after treatment in patients receiving regular 
intravenous immunoglobulin infusions as part of their standard NHS care. If there is a true 
correlation between these variables, it would be expected that similar changes with treatment 
would be observed.  
It is hoped to gain insights into the pathophysiology of fatigue in demyelinating disorders of the 
peripheral nervous system, which may lead to identification of biomarkers that could be useful to 
monitor treatment response and may be useful in future therapeutic trials.  
 
  






All patients with CIDP and CMT1A attending specialist Neuromuscular Clinics at the Queen Elizabeth 
Hospital, Birmingham, were invited to participate, irrespective of treatment status. The rationale for 
inviting this cohort was regular attendance at follow-up appointments, aiding study recruitment. 
Patients were approached at routine clinic visits and provided with study information leaflets. They 
were subsequently contacted by telephone to arrange a study appointment.   
Inclusion criteria were age 18 years and older, with CIDP meeting diagnosis of “definite” or 
“probable” CIDP as per EFNS/PNS Guidelines31 and diagnosis of CMT1A confirmed by genetic studies. 
Exclusion criteria included co-morbid conditions contributing to fatigue; known malignancy, 
psychiatric diagnosis preceding onset of the neuropathy, anaemia, hypothyroidism, obstructive sleep 
apnoea, cardiac or pulmonary disorders. Patients with permanent pacemakers or implantable 
cardioverter defibrillators (ICDs) were also excluded due to theoretical risks associated with 
electrical stimulation during electrophysiology studies. 
All patients with CIDP and CMT attended an initial appointment where clinical assessments, 
electrophysiological and MUNIX studies were performed. Patients with CIDP also attended a repeat 
appointment. For CIDP patients receiving regular IVIg therapy the initial appointment was scheduled 
immediately prior to a planned infusion, with a repeat assessment performed at the midpoint 
between infusions. For example, if a patient was receiving infusions with a 4 week interval, the 
repeat assessment was performed 2 weeks after the infusion. Identical clinical assessments, 
electrophysiological and MUNIX studies were performed at both appointments. 
Healthy control subjects were recruited from hospital colleagues as part of preliminary component 
of this study, undergoing MUNIX and physiological fatigue studies. 
4.2 Assessment methods 
4.2.1 Self-report scales 
Experienced fatigue was assessed using the linearly-weighted modified Rasch-built fatigue severity 
scale (R-FSS)76. In addition, the checklist of individual strength (CIS), was used to provide a 
multidimensional assessment of patients’ experience of fatigue83,103,104.  
Disability was assessed using the linearly-weighted Rasch-built overall disability sum score (R-ODS), 
which was developed for use in patients with immune-mediated polyneuropathies and has good 




test-retest reliability and validity115. A second disability scale, the widely used overall neuropathy 
limitations scale (ONLS) was also used116. 
The Hospital Depression and Anxiety scale (HADS)117 was used to assess for co-morbid depression 
and anxiety, which may contribute to fatigue. This 14-item questionnaire has separate subscales for 
depression and anxiety, with a score of 0 to 7 out of a maximum of 21 for each subscale considered 
normal. Finally, the medical outcomes study 36-item short form health survey (SF-36) adapted into 
English (United Kingdom) was used to assess self-reported, health-related quality of life106. The 
survey contains subscales for 8 domains; physical functioning, role-physical, bodily pain, general 
health, vitality, social functioning, role-emotional and mental health. These domains can be 
combined to form a physical component summary and mental component summary. Norm-based 
scores in each subscale range from 0-100 and allow comparison with data drawn from a general UK 
population. Higher scores indicate better functioning, with an average score of 50 for each subscale. 
4.2.2 Clinical assessments 
Muscle strength was assessed using Medical Research Council (MRC) grading118 and maximal grip 
strength using a hand-held Jamar grip dynamometer119. MRC grading (range 0-5) of shoulder 
abduction, elbow flexion, wrist extension, finger abduction, hip flexion, knee flexion, ankle 
dorsiflexion and hallucis dorsiflexion was assessed bilaterally, giving a maximal score possible of 80. 
Lower scores correspond to greater degree of abnormality. 10-metre timed walking test was used to 
assess “focal disability”120. 
Sensory function was assessed using the modified INCAT sensory sum score, incorporating revised 
assessment of two-point discrimination assessment121,122. This sensory sum score assesses fine 
touch, pin-prick, vibration and proprioception (range 0-4) in upper and lower limbs and two-point 
discrimination (range 0-1) in upper limbs only, giving a maximum score of 33, with higher scores 
corresponding to greater degree of abnormality. Sensory function was also assessed using a Rydell-
Seiffer tuning fork123, calculating a sum score for vibration thresholds at the interphalangeal joint of 
hallucis, the medial malleolus, the patella, the distal interphalangeal joint of the index finger, the 
ulnar styloid and the medial epicondyle of the humerus. A maximal score of 48 is possible with lower 
scores corresponding to greater degree of abnormality. 
4.2.3 Electrophysiological assessment 
Nerve conduction studies were performed according to standard protocols124 using a Dantec™ 
Keypoint® Focus machine. All studies were performed unilaterally on the dominant side. Skin surface 




temperature was checked and raised to above 32°C in the hands and 30°C in the feet prior to testing. 
Antidromic sensory NCS of sural and superficial radial nerves and orthodromic sensory NCS of 
median and ulnar nerves were performed measuring amplitude and sensory conduction velocity. 
Median nerve motor NCS were performed recording from abductor pollicis brevis (APB) and 
stimulating at the wrist, elbow and axilla. Ulnar nerve motor NCS were performed recording from 
the abductor digiti minimi (ADM) and stimulating at the wrist, below the elbow, above the elbow 
and axilla. Tibial nerve motor NCS were performed recording from the abductor hallucis (AH) and 
stimulating posterior to the medial malleolus and popliteal fossa. Peroneal nerve motor NCS were 
performed recording from the extensor digitorum brevis (EDB) and stimulating at the ankle, below 
and above the fibular head. For each motor NCS, distal motor latency (DML), onset-to-peak 
amplitude, negative peak area, negative peak duration, minimum F-wave latency and F-wave 
persistence were evaluated. Average values for each parameter were calculated by summation then 
division by the number of nerves from which values could be recorded. Motor conduction block is 
classified according to published guidelines125. 
MUNIX and MUSIX sum scores were recorded from 3 muscles, again on the dominant side; APB, 
ADM and tibialis anterior (TA). An active electrode was placed over the muscle belly and a reference 
electrode was placed over the proximal thumb interphalangeal joint (for ABP), the fifth metacarpal-
phalangeal joint (for ADM) and the distal tibia (for TA). Published descriptions of the technique were 
followed60,61.  Firstly, a supramaximal CMAP was recorded from the muscle being studied (see Figure 
1A). Amplitude, area and power were calculated from the negative peak of the CMAP126. 
Secondly, surface interference patterns (SIP) were recorded using identical electrode positioning, 
asking the patient to perform 10 isometric muscle contractions ranging from 10-100% of maximal 
force whilst the examiner applied resistance (see Figure 1B). SIP was recorded in 300ms epochs for 
each contraction, using filter settings of 3-3000Hz127,128. SIP area and power were calculated from 
each epoch.  
Finally, area and power of the CMAP and all SIP epochs were transferred to a mathematical formula 
developed by Nandedkar and colleagues60,61. Ideal case motor unit count (ICMUC) was calculated 
from the following formula: 
 ICMUC = (Cp x Sr)/(Cr x Sp) 
 





Figure 1: A) Compound muscle action potential recorded from abductor pollicis brevis stimulating the 
median nerve at the wrist. B) Surface interference patterns recorded from abductor pollicis brevis at 
increasing force levels. C) Plot of ideal case motor unit count against surface interference pattern 
area, demonstrating calculation of MUNIX and MUSIX values. Data acquired using a Dantec™ 
Keypoint® Focus system. 
Cp and Cr refer to the power and area of the CMAP, respectively, and Sp and Sr refer to the power 
and area of the SIP. The parameter calculated is referred to as “ideal case” as the mathematical 
model makes the assumptions that all individual motor unit potentials have identical area and do 
not overlap during muscle contraction. For each SIP epoch, ICMUC is plotted on a graph against SIP 
area (see Figure 1C). SIP area is used as an indirect correlate of force. Henneman’s size principle 
states that at low levels of isometric muscle contraction, smaller motor units are recruited, with 
larger motor units recruited as the force of muscle contraction increases129. Therefore, area of the 
SIP increases as force of muscle contraction increases.  
Regression modelling was performed using the equation: 
 ICMUC = A (Sr)α 
MUNIX was arbitrarily defined as the ICMUC when Sr=20, corresponding to a very low level of force: 
 MUNIX = A (20)α  




Finally, MUSIX was calculated by: 
 MUSIX = CMAP amplitude (µV) /MUNIX  
4.2.4 Physiological fatigue 
Assessment of physiological fatigue was performed using protocols adapted in provisional trials in 
healthy controls. Force of grip strength during a maximal muscle contraction is assessed using a 
Vernier® grip dynamometer sampling at 10Hz. Data is collected in LoggerLite® software before being 
transferred to Microsoft Excel for further analysis. Patients are sat comfortably in a chair with the 
elbow flexed at 90 degrees and the forearm resting on a pillow. Three brief maximal contractions are 
performed initially to assess consistency of response. Patients are then instructed to perform 
maximal grip and attempt to maintain this for 60 seconds, stopping in the event of any discomfort. 
Constant visual feedback is provided regarding grip strength. Average force is calculated for each 1 
second epoch, with physiological fatigue defined as the force of grip strength at the end of the 





























Change in force of grip strength and RMS of the rectified SEMG 
over time during maximal voluntary contraction
Root mean square Force
Figure 2: Graph demonstrating decline in force of grip strength (solid blue line) and root mean 
square (RMS) of the rectified surface EMG signal (dashed line) over time during a fatiguing 
contraction (both values are expressed as % of the initial value). Recordings taken from a 32-
year-old male with no history of neurological disease. In this example physiological fatigue is 
calculated as 54.0% with a corresponding decline in RMS of 61.9% 




SEMG was recorded simultaneously using an active recording electrode placed over forearm flexor 
muscles (flexor digitorum superficialis) and a reference electrode over the lateral aspect of the wrist. 
One second epochs of SEMG activity are recorded every 2 seconds using Dantec™ Keypoint® 
software, calculating average root mean square of the rectified SEMG signal for each epoch (See 
Figure 2). 
Finally, after a rest period of at least 10 minutes, patients were asked to maintain grip strength 
corresponding to roughly 30% of maximal grip strength. The rationale for this procedure was to 
assess SEMG activity during maximal and submaximal contractions. It was hypothesised that patients 
with fewer functioning motor units would require a greater proportion of the available pool to 
maintain a submaximal contraction, and as a result root mean square of the SEMG signal would be 
similar during maximal and submaximal contractions in patients with lower MUNIX values. RMS of 
the SEMG signal during submaximal contraction is expressed as a percentage of RMS at the 
beginning of maximal contraction. 
4.3 Statistical analysis 
4.3.1 Sample size calculation 
In contrast to previous studies exploring fatigue in this patient population, this study utilises a 
linearly-weighted scale for assessment of fatigue. Sample size calculation therefore relies on ability 
to detect a significant correlation between two variables under investigation. In our primary 
outcome measure, this is the correlation between experienced fatigue and MUNIX values. No 
previous studies have investigated the correlation between these variables, making a priori 
determination of a correlation coefficient difficult. However, Delmont and colleagues130 have 
demonstrated strong correlation between MUNIX values and two disability scales in patients with 
CIDP (Spearman’s Rank correlation coefficients of 0.70 and 0.71).  
Under the assumption we expect to see similar correlation coefficients, we can use the technique 
described by Bland131 to determine the required sample size. Using an α value of 0.05 and a power 
(β) of 90%, a minimum sample size of 17 would be required to determine whether the correlation 
between these two variables differs from zero. 
4.3.2 Descriptive statistics 
Distribution of all variables was assessed using the one-sample Kolmogorov-Smirnov test. Parametric 
data is presented as mean values and standard deviation. Nonparametric data is presented as 
median values and interquartile ranges. 




4.3.3 Intraclass correlation coefficient 
Intraclass correlation coefficient (ICC) was used to assess test-retest reliability of MUNIX in healthy 
controls using a 2-way, mixed effects model looking for absolute agreement. ICC values nearer 1.0 
indicate greater similarity between results, with ICC greater than 0.9 indicating excellent 
reliability132. ICC values of 0.75 to 0.9 were taken to indicate good reliability and values of 0.5 to 0.75 
were taken to indicate moderate reliability133. 
4.3.4 Association analysis 
For parametric variables, differences between the three groups were assessed one-way ANOVA with 
post-hoc Bonferroni correction for multiple comparisons. Differences between CIDP patients 
receiving treatment and not receiving treatment were assessed using independent, two-tailed 
student t-test. For non-parametric variables, differences between the three groups were assessed 
using the independent-samples Kruskal-Wallis test with post-hoc Bonferroni correction for multiple 
comparisons. Changes in variables across repeat appointments were assessed using paired, two-
tailed student t-test for parametric variables and Wilcoxon signed ranks test for nonparametric 
variables.  
4.3.5 Correlation and regression analysis 
Association between individual numerical variables was assessed using correlation analysis. Pearson 
correlation coefficient was used to assess statistical association between variables with normal 
distribution. Correlation analysis in nonparametric data was performed using Spearman’s Rank 
correlation. For both analyses, an alpha value of <0.05 is deemed significant. 
Multivariate stepwise linear regression analysis was used in the CIDP patient group, with probability 
of F to enter of <0.05 and to remove of <0.1. Only variables showing significant correlation in the 
univariate analysis were included in the regression model. Dependent variables are identified in the 
relevant sections.  
All statistical analysis was performed using IBM SPSS® software version 25 (SPSS Inc., Chicago, IL).  




5 Ethical considerations 
Control data were collected from healthy volunteers (hospital staff) as part of a provisional 
component of this study. Ethical approval was granted from the Queen Elizabeth Hospital research 
department. 
Ethical approval for the main component of the study involving recruitment and assessment of 
patients from an NHS hospital has been granted from the NHS Health Research Authority (IRAS 
project ID: 206150, REC reference 17/LO/0798, Protocol number 162-2016-YR). Local ethical 
approvals are in place from the University Hospitals Birmingham Research and Development 
Governance Office (project reference RRK 5804) and Aston University, who are acting as the sponsor 
for this study (AHRIC ref no: 162-2016-YR). 
As part of the ethical application, patient information sheets, consent forms and GP letters were 
drafted. These are included in Appendices 2, 3 and 4, respectively. 
A minor amendment to the study protocol was made in June 2018 to prolong the period of 
recruitment and allow patients identified on screening of clinic lists to be contacted directly by the 
clinical team, with the aim of improving recruitment to the study.  
The major ethical considerations of this study are: 
• Safety of research participants 
The techniques being employed in this research study are very low risk. Nerve conduction studies 
utilise small electrical pulses in the range of 1-100mA to stimulate peripheral nerves and are widely 
used in clinical practice without complication134. Prior to undertaking the study, a thorough risk 
assessment was undertaken. There is a theoretical risk of leakage currents from electrical equipment 
used to perform nerve conduction studies. In order to minimise this risk all equipment underwent 
PAT testing prior to study commencement and ground electrodes are used throughout. Patients are 
disconnected from stimulators when equipment is turned on or off as theoretically the risk of 
current leakage is greater at these times. Patients with permanent cardiac pacemakers and 
implantable defibrillators may be at increased risk during electrical nerve stimulation as the 
pacemaker/defibrillator leads provide a lower resistance pathway for electrical current to reach the 
heart. Patients with these devices were excluded from the study. 
• Informed consent 




All potential participants are approached through the existing clinical team and provided with 
written information regarding the study. They are given a period of time to consider the information 
before being contacted again to decide whether they wish to participate. It is re-emphasised at this 
point that the study is optional and should they choose to decline or withdraw at a later date it will 
not affect their existing clinical care. With the exception of transient fatigue, no potential risks are 
envisaged. On their first study visit, participants are given the opportunity to ask questions and are 
taken through the consent form. Informed consent is taken by one of the study investigators (AL), 
who has training in taking informed consent as part of medical training and Good Clinical Practice 
qualification. 
• Confidentiality 
Potential participants are identified through screening of clinic lists at the Queen Elizabeth Hospital, 
Birmingham. A database of potentials participants is stored electronically in a password protected 
folder on an NHS computer system, which only the study investigators have access to. Each patient is 
given a unique identification code, used on all research data subsequently collected at Aston 
University. All research data is stored securely in a locked filing cabinet at Aston Brain Centre. 
• Plan for action in adverse events 
As mentioned previously, this study employs low-risk methods for assessment. However, unforeseen 
events such as trips, falls and intercurrent illness need to be considered. Standard operating 
procedures are in place at Aston University for these potential adverse events. Participants are seen 
only on days when at least two staff members with intermediate life support training are available. 
Standard operating procedures for notification of medical staff are in place should a participant 
become unwell during their study visit. 
 
  





6.1 Demographic data 
Twenty healthy control subjects were recruited from hospital staff. Ten were female and age range 
was 29–80y; mean age 44.4y (13.9). 
Forty-three patients with CIDP were identified. Of these 9 met exclusion criteria and a further 8 
declined invitation to participate.   Twenty-six patients with CIDP were included (5 female; age range 
49–79y; mean age 62.5y (9.5)). Average time between diagnosis of CIDP and enrolment was 61 
months. All patients were clinically stable; 15 undergoing regular IVIg therapy at 3 to 6 weekly 
intervals; 1 receiving subcutaneous immunoglobulins and 9 receiving physiotherapy input only.  
Thirty-five patients with a genetically-confirmed diagnosis of CMT1A were identified.  Of these 6 met 
exclusion criteria and 7 patients could not be contacted. One patient was unable to provide 
informed consent and 6 patients declined invitation to participate.  Fifteen patients with CMT1A 
were included (11 female; age range 21-70y; mean age 47y (15.3)). Further clinical details of 
recruited patients are provided in Tables 2 and 3. 
CIDP patients attended repeat appointments. All 15 patients receiving IVIg therapy were seen 2 to 3 
days prior to a planned infusion and had a repeat appointment on average 15 days after the 
infusion. In addition, 5 patients with CIDP not receiving regular IVIg therapy also attended a repeat 






Patient ID Age 
(years) 






Co-morbid medical conditions Current medication 
CIDPF001 79 F 36 IVIg Yes Hypertension Indapamide 
CIDPM002 49 M 21 IVIg Yes Depression Folic acid, Lansoprazole, 
Sertraline 
CIDPM003 68 M 24 IVIg Yes Mild thrombocytopenia Nil 
CIDPF005 74 F 7 IVIg Yes  Nil 
CIDPM006 61 M 19 IVIg Yes Hypertension, Chronic leg ulcer Lansoprazole, Gabapentin, 
Atenolol, Dipyridamole 
CIDPM007 75 M 36 IVIg Yes IgG paraproteinaemia Propranolol, Alendronate, 
Gabapentin 




CIDPM009 74 M 14 IVIg Yes Hypertension, GORD, prostatitis Lansoprazole, Indapamide 
CIDPM010 70 M 43 IVIg Yes Hypertension, Depression Citalopram, Alendronate, Adcal 
D3, Ramipril 
CIDPM011 61 M 192 Physio  Hypertension Nil 
CIDPM012 58 M 12 Physio Yes Asthma Inhalers, Pregabalin 
CIDPF013 52 F 99 IVIg Yes  Lansoprazole, Adcal D3, 
Alendronate 
CIDPM014 60 M 19 IVIg Yes Type II Diabetes Mellitus, 
Hypertension, CKD stage III 
Linagliptin, Amlodipine, 
Doxazosin, Bisoprolol, 
Furosemide, Vitamin D 




CIDPM016 70 M 264 IVIg Yes IgM paraproteinaemia Alendronate, Adcal D3 
CIDPM017 52 M 17 Physio   Nil 
CIDPM018 62 M 36 IVIg Yes  Lansoprazole, Co-codamol 
CIDPM019 68 M 15 Physio  Hypertension, Hypercholesterolemia Perindopril, Lercanidipine 
CIDPF020 53 F 72 IVIg Yes  Nil 
CIDPM021 49 M 23 Physio Yes Depression Citalopram, Paracetamol, 
Pregabalin 








CIDPM023 56 M 20 Physio  Depression, Hypertension, GORD Aspirin, Ranitidine, Lisinopril, 
Atorvastatin, Citalopram, 
Bisoprolol 
CIDPM024 57 M 168 SCIg  Gout Nil 




CIDPM026 51 M 36 IVIg Yes Monoclonal gammopathy of 
undetermined significance 
Nil 
CIDPM027 78 M 276 Physio  Asthma, Hypertension Aspirin, Lansoprazole, 
Bendroflumethiazide 
Table 2: Clinical details of recruited patients with chronic inflammatory demyelinating polyneuropathy. IVIg=intravenous immunoglobulins; 
SCIg=subcutaneous immunoglobulins; CKD=chronic kidney disease; GORD=gastro-oesophageal reflux disease 
  





Patient ID Age (years) Sex Co-morbid medical conditions Current medication 
CMTF001 63 F  Amitriptyline 
CMTF002 44 F  Nortriptyline 
CMTF003 43 F Benign paroxysmal positional vertigo Pregabalin 
CMTF004 37 F  Nil 
CMTF005 38 F  Sertraline 
CMTM006 67 M Hypertension, Gout Colchicine, Doxazosin, Indapamide, Quinine 
Sulphate, Ramipril 
CMTF007 71 F  Alendronate 
CMTM008 24 M  Oxycodone, Pregabalin 
CMTF009 54 F Restless leg syndrome Gabapentin 
CMTM010 63 M Asthma, Eczema, Type II Diabetes 
Mellitus (diet controlled) 
Inhalers 
CMTF011 43 F GORD Gaviscon 
CMTM012 48 M  Nil 
CMTF013 32 F  Mirtazapine, Lansoprazole, Co-codamol 
CMTF014 57 F  Adcal D3, Amitriptyline, Lansoprazole, Solifenacin 
CMTF015 21 F  Nil 





6.2 MUNIX: normative data and assessment of intra-rater reliability 
MUNIX and MUSIX values showed normal distribution in healthy controls. Mean MUNIX sum scores 
were 516.9 (91.4) and mean MUSIX sum scores were 178.5 (32.2). Values compared to previously 
published reports, including from individual muscles, are shown in Table 5. 
All controls underwent repeat studies at least 1 month later performed by the same investigator. 
ICCs are shown in Table 4. All MUNIX and MUSIX values demonstrated good reliability (ICC between 
0.75 and 0.9), except for ADM MUSIX, TA MUNIX and TA MUSIX. MUNIX sum scores demonstrated 
higher ICC values than any of the individual muscles, and MUSIX sum scores demonstrated higher 
ICC values than any individual muscle except for APB.  
 
Figure 3: Flowchart detailing patient recruitment to the study. CIDP=chronic 
inflammatory demyelinating polyneuropathy; CMT=Charcot Marie Tooth disease; 
IVIg=intravenous immunoglobulins; SCIg = subcutaneous immunoglobulins 




Muscle MUNIX ICC 95% CI MUSIX ICC 95% CI 
APB 0.78 0.52-0.91 0.80 0.56-0.92 
ADM 0.75 0.48-0.89 0.58 0.22-0.81 
TA 0.53 0.14-0.78 0.24 -0.18-0.60 
Sum scores 0.85 0.67-0.94 0.75 0.48-0.89 
Table 4: Intraclass correlation coefficients (ICC) for MUNIX and MUSIX calculated from individual 
muscles and sumscores calculated from all three muscles combined. APB=abductor pollicis brevis, 















n= 20 66 24 20 28 
Mean age (years) 44.4 49 62 46.7 64 
MUNIX mean (SD) 195.8 (50.0) 145.7 (54.4) 121 (31) 198 (NR) 133* 
MUSIX mean (SD) 65.0 (19.8) NR 71 (13) 60 (NR) 61.9* 










n= 20 34 62 66 48 28 
Mean age (years) 44.4 48 NR 49 44.4 64 
MUNIX mean (SD) 176.1 (40.5) 158 (40) 142 (42) 162.9 (47) 176 (46) 134* 
MUSIX mean (SD) 66.5 (14.0) 68 (13) NR NR NR 68* 







n= 20 66 30 28 
Mean age (years) 44.4 49 62 64 
MUNIX mean (SD) 145.1 (36.8) 132 (38.4) 103 (26) 102* 
MUSIX mean (SD) 47.0 (6.5) -- 53 (7.3) 51* 
Sum scores This study Delmont 
(2016)130  
 
n= 20 28 
Mean age (years) 44.4 64 
MUNIX mean (SD) 516.9 (91.4) 379* 
MUSIX mean (SD) 178.5 (32.2) 184* 
 
Table 5: Normative data for MUNIX and MUSIX values recorded from abductor pollicis brevis (APB), abductor digitii minimi (ADM) 







6.3 MUNIX: values in patients and correlations with clinical assessments 
 6.3.1 MUNIX and MUSIX values 
Mean MUNIX values in CIDP patients were 94.3 (59.6) for APB, 73.4 (49.0) for ADM and 46.3 (41.7) 
for TA. Mean MUSIX values were 92.8 (46.5) for APB, 105.8 (59.3) for ADM and 61.5 (29.2) for TA. 
Mean MUNIX sum score was 214.0 (124.4) and mean MUSIX sum score 251.2 (96.2). Mean MUNIX 
values in CMT patients were 52.3 (38.8) for APB, 54.1 (36.3) for ADM and 33.3 (37.8) for TA. Mean 
MUSIX values were 95.6 (36.1) for APB, 86.6 (56.7) for ADM and 40.6 (31.0) for TA. Mean MUNIX 
sum score was 139.7 (87.3) and mean MUSIX sum score 222.8 (88.8). 
MUNIX sum scores were significantly lower in patients with both CIDP and CMT compared to 
controls (p<0.001). Although lower MUNIX values were observed in CMT patients compared to CIDP 
patients, this did not reach statistical significance (p=0.095). Mean MUSIX sum scores were higher in 
patients with both CMT and CIDP compared to controls. However, no statistically significant 
differences were observed between MUSIX sum scores in any of the groups (see Figure 4). 
No difference was found between MUNIX or MUSIX sum scores in CIDP patients on treatment versus 
untreated patients (p=0.343 and p=0.947, respectively). 
 
Figure 4: Scatterplots comparing MUNIX and MUSIX sum scores in healthy control subjects, CIDP 






6.3.2 Correlations with clinical assessments and self-report scales 
Median MRC muscle strength sum score in CIDP patients was 73.5 (59.3-78.0) out of 80. Mean grip 
strength was 26.9kg (13.4) with no significant difference observed between hands. Mean INCAT 
sensory sum score was 7.3 (4.6) and vibration threshold sum score 27.2 (10.2). Median 10m walk 
time was 10.4s (8.3-14.2). Mean R-ODS was 56.7 (16.6) and mean ONLS was 3.7 (2.1).  
Vibration threshold sum scores were higher in untreated than treated CIDP patients at baseline 
(mean value 33.4 vs 23.9, respectively; p=0.043). No significant differences were seen in any of the 
other assessments. 
Positive linear correlation, assessed using Pearson correlation coefficient, was observed between 
MUNIX sum scores and MRC sum score (r=0.696, p<0.001), hand grip strength (r=0.412, p=0.037), 
vibration threshold sum score (r=0.618, p=0.001) and R-ODS (r=0.480, p=0.013). Negative linear 
correlation was observed in CIDP patients between MUNIX and MUSIX sum scores (r=-0.439, 
p=0.025), INCAT sensory sum score (r=-0.598, p=0.001) and ONLS (r=-0.607, p=0.001) (see Figure 5). 
No significant correlation was observed between MUNIX sum scores and patient age, time since 
diagnosis or 10 metre timed walk test. Positive linear correlation was observed between MUSIX sum 
scores and patient age (r=0.419, p=0.033) but none of the other variables. 
Median MRC muscle strength sum score in CMT patients was 68.0 (57.0-72.0) out of 80. Mean grip 
strength was 24.2kg (7.5) with no significant difference observed between hands. Mean INCAT 
sensory sum score was 9.9 (2.8), with a mean vibration threshold sum score of 23.9 (8.6). Median 
10m timed walk test was 9.5s (8.8-12.1). Mean ONLS was 3.4 (1.7) and mean R-ODS score was 62.3 
(16.3).  
Positive linear correlation, assessed using Pearson correlation coefficient, was observed between 
MUNIX sum scores and MRC muscle strength sum score (r=0.816, p<0.001), hand grip strength 
(r=0.693, p=0.004) and vibration threshold sum score (r=0.703, p=0.003). Negative linear correlation 
was observed between MUNIX sum scores and INCAT sensory sum scores (r=-0.703, p=0.003) and 
ONLS scores (r=-0.824, p<0.001) (see Figure 6). 
In contrast to CIDP patients, a negative correlation was also observed between MUNIX sum scores 
and patient age (r=-0.688, p=0.005) and between MUNIX sum scores and 10 metre timed walk test 
(r=-0.577, p=0.024). No significant correlation was observed between MUNIX sum scores and R-ODS 
scores. 
No significant correlation was observed between MUSIX sum scores and any of the CMT patient 
demographic data or any of the clinical assessments.  




In CIDP patients, only F-wave persistence showed similar correlations with the clinical assessments 
as those demonstrated by MUNIX, although higher correlation co-efficients were seen with MUNIX 
sum scores. Similar correlation with clinical assessments was not observed with any of the other 
electrophysiological parameters. In CMT patients, proximal CMAP amplitude and proximal CMAP 
area showed similar correlations with the clinical assessments as those demonstrated by MUNIX. 
Again, in general higher correlation co-efficients were seen with MUNIX sum scores. However, both 
proximal CMAP amplitude and CMAP area demonstrated positive correlation with R-ODS score, 
which was not observed with MUNIX sum scores.  Details of electrophysiological studies and 
correlation analysis in patients with CIDP and CMT are included in Appendix 5 and Appendix 6. 





Figure 5: CIDP patients. Correlation between MUNIX sumscores and (a) Rasch-built overall 
disability score, R2=0.23, Pearson correlation coefficient 0.48 (p=0.013), (b) Overall 
neuropathy limitations scale, R2=0.37, Pearson correlation coefficient -0.61 (p=0.001), (c) MRC 
muscle strength sumscores, R2=0.49, Pearson correlation coefficient 0.70 (p<0.001), (d) Grip 
strength assessed using a Jamar-grip dynamometer, R2=0.17, Pearson correlation coefficient 
0.41 (p=0.037), (e) INCAT sensory sumscore, R2=0.36, Pearson correlation coefficient 0.60 
(p=0.001), (f) Vibration threshold sumscore assessed using a Rydell-Seiffer tuning fork, 
R2=0.38, Pearson correlation coefficient 0.62 (p=0.001). Graph shows best-fit line and 95% 
confidence band of best-fit line. 





Figure 6: CMT patients. Correlation between MUNIX sumscores and (a) Overall neuropathy 
limitations scale, R2=0.68, Pearson correlation coefficient -0.824 (p<0.001), (b) MRC muscle strength 
sumscores, R2=0.67, Pearson correlation coefficient 0.816 (p<0.001), (c) Grip strength assessed using 
a Jamar-grip dynamometer, R2=0.48, Pearson correlation coefficient 0.693 (p=0.004), (d) INCAT 
sensory sumscore, R2=0.49, Pearson correlation coefficient -0.703 (p=0.003), (e) Vibration threshold 
sumscore assessed using a Rydell-Seiffer tuning fork, R2=0.50, Pearson correlation coefficient 0.703 
(p=0.003), (f) Timed 10 metre walk test, R2=0.33, Pearson correlation coefficient -0.577 (p=0.024) 
Graph shows best-fit line and 95% confidence band of best-fit line 
 




6.4 Assessment of physiological fatigue utilising hand-grip dynamometry 
Assessment of physiological fatigue was performed using grip strength in the dominant hand. 
Maximal grip strength at baseline was significantly higher in controls compared to CIDP and CMT 
patients (38.9kg (12.8) vs 24.2kg (7.5), p=0.007 and 38.9kg (12.8) vs 28.6kg (14.5), p=0.043, 
respectively).  
Fifteen controls, all CIDP patients and 11 CMT patients completed the physiological fatigue 
assessments. Decline in force during 1-minute of maximal grip strength was greater in controls 
(median value 56.4% (41.2-64.6)) compared to CMT patients (39.4% (29.5-49.4), p=0.039). Median 
decline in force in CIDP patients was 49.3% (42.2-53.8), demonstrating no statistically significant 
difference compared to CMT patients (p=0.425) or controls (p=0.473). 
A greater decline in RMS of the SEMG signal during the 1-minute grip strength test was observed in 
controls compared to both CMT and CIDP patients. Median decline in RMS in controls was 56.3% 
(30.8-68.3) compared to 19.0% (11.7-36.6) in CIDP patients (p=0.010) and 30.4% (-2.4-36.3) in CMT 
patients (p=0.040). No difference was observed between CIDP and CMT patients (p=1.000). Decline 
in force of grip strength and RMS of the SEMG signal are illustrated in Figure 7. 
RMS of the SEMG signal was compared during maximal grip strength and whilst maintaining a grip 
strength at 30% of the maximum grip strength. In control subjects, median RMS of the SEMG signal 
was 28.2% (20.9-34.1) during this assessment. Higher values were seen in both CIDP patients (46.5% 
(31.2-58.4), p=0.006) and CMT patients (42.7% (35.7-51.1), p=0.073), albeit not reaching statistical 
significance in CMT patients. No significant difference was observed between CMT and CIDP patients 
(p=1.000).  
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Figure 7: Graphs demonstrating decline in force of grip strength during 1 minute of maximal 
voluntary contraction (solid line) and corresponding decline in root mean square of the rectified 
surface EMG signal recorded from forearm flexors (dashed line), in A) controls (n=15), B) CIDP 
patients (n=26) and C) CMT patients (n=11). Graphs show median values expressed as a percentage 
of the initial median value. Error bars show first and third quartiles. 
6.4.1 Physiological fatigue and MUNIX 
Relationship between physiological fatigue and peripheral motor unit number, as assessed using 
MUNIX values, were assessed using Spearman’s Rank correlation analysis. As described in section 
6.2.3, MUNIX sum scores showed positive linear correlation with maximal grip strength at baseline. 
However, in CIDP patients, MUNIX sum scores showed no significant linear correlation with decline 
in grip strength (r=-0.045, p=0.827), decline in RMS of the rectified SEMG signal (r=0.138, p=0.500) or 
RMS of the rectified SEMG signal during submaximal contraction (r=-0.341, p=0.088). In CMT 
patients, MUNIX sum scores also showed no significant linear correlation with decline in grip 
strength (r=-0.236, p=0.484) or decline in RMS of the rectified SEMG signal (r=0.19, p=0.958). There 
was negative linear correlation between MUNIX sum scores in CMT patients and ratio of RMS during 
maximal compared to submaximal contraction (r=-0.664, p=0.026). MUSIX sum scores showed no 
significant linear correlation with any of the parameters used to assess physiological fatigue in either 
patient group. 
6.5 Assessment of experienced fatigue and health-related quality of life 
Experienced fatigue was assessed using both the Rasch-built Fatigue Severity Scale (R-FSS) and the 
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higher scores indicating higher level of self-reported experienced fatigue. Subdomains of the CIS 
(maximum scores for each subdomain in brackets) include subjective feeling of fatigue (56), 
concentration (35), motivation (28) and physical activity (21).  Median R-FSS score in CIDP patients 
was 17 (13.5-19) and median CIS score was 77.5 (61-98.8). Median scores in CIS subdomains in CIDP 
patients were; subjective feeling of fatigue 40 (33-47.3), concentration 12.5 (7.5-18), motivation 13.5 
(9.5-16.8) and physical activity 12 (7.3-17).  
Median R-FSS score in CMT patients was 13 (8.5-19) and median CIS score was 88 (59.5-108). 
Median scores in each CIS subdomain in CMT patients were; subjective feeling of fatigue 44 (26-
50.5), concentration 24 (11.5-26), motivation 16 (7.5-19) and physical activity 12 (5.5-15).  
Health-related quality of life was assessed using the medical outcomes study 36-item short form 
health survey (SF-36). Norm-based scores in each subscale range from 0-100 and allow comparison 
with data drawn from a general UK population, with an average score of 50 for each subscale (see 
Figure 8). In contrast to the experienced fatigue scores, higher scores indicate better functioning or 
less pain. In CIDP patients, median physical components sum score was 34.8 (28.4-44.9) and median 
mental components sum score was 57.2 (48.1-59.3). In CMT patients, median physical components 
sum score was 35.0 (32.3-43.9) and median mental components sum score was 42.8 (39.8-55.4). 
Data from all assessments, including more detail of SF-36 subscales, are provided in Table 6.  
  
A B 
Figure 8: Charts showing norm-based scores for each subscale of the medical outcomes study 36-item, short 
form health survey (SF-36) in A) CIDP patients and B) CMT patients. PCS= physical components summary, 
MCS=mental components summary, PF=physical functioning, RP=role physical, BP=bodily pain, GH=general health, 
VT=vitality, SF=social functioning, RE=role emotional, MH=mental health 




 CIDP CMT p-value 
R-FSS (/21) 17 (13.5-19) 13 (8.5-19) 0.398 
    
CIS overall (/130) 77.5 (61-98.8) 88 (59.5-108) 0.495 
CIS-subjective fatigue (/56) 40 (33-47.3) 44 (26-50.5) 0.512 
CIS-concentration (/35) 12.5 (7.5-18) 24 (11.5-26) 0.968 
CIS-motivation (/28) 13.5 (9.5-16.8) 16 (7.5-19) 0.355 
CIS-physical activity (/21) 12 (7.3-17) 12 (5.5-15) 0.305 
    
SF-36     
Physical functioning NBS 32.7 (27.4-43.7) 36.5 (28.8-47.5) 0.305 
Role physical NBS 32.5 (30.2-45.9) 38.1 (30.8-41.4) 0.944 
Bodily pain NBS 49.1 (38.3-60.4) 46.7 (39.2-50.3) 0.347 
General health NBS 38.9 (30.8-52.6) 39.6 (30.8-43.7) 0.790 
Vitality NBS 46.7 (38.5-51.9) 37.7 (32.5-48.1) 0.200 
Social functioning NBS 47.3 (38.5-52.3) 37.3 (32.3-46.1) 0.130 
Role emotional NBS 52.7 (42.2-56.2) 49.2 (35.3-55.3) 0.254 
Mental health NBS 53.5 (48.3-56.1) 45.6 (40.4-52.8) 0.098 
Physical components sumscore NBS 34.8 (28.4-44.9) 35.0 (32.3-43.9) 0.585 
Mental components sumscore NBS 57.2 (48.1-59.3) 42.8 (39.8-55.4) 0.033 
Table 6: Results from Rasch-built Fatigue Severity Scale (R-FSS), Checklist of Individual Strength (CIS) 
and the medical outcomes study 36-item short form health survey (SF-36) in patients with CIDP and 
CMT. Data expressed as median values (interquartile range). Differences between groups compared 
with Mann-Whitney U Test.  
 
Co-morbid depression and anxiety were assessed using the Hospital Anxiety and Depression Scale 
(HADS). Six of the 26 CIDP patients scored in the range indicating high likelihood of depression (11 or 
more), with 2 of these also scoring in range indicating high likelihood of an anxiety disorder. 2 of the 
15 CMT patients scored in the range indicating high likelihood of both depression and anxiety 
disorders. A further 3 CIDP patients and 4 CMT patients scored in the borderline range for 
depression (score of 8 to 10).  
Positive linear correlation, assessed using Spearman’s rank correlation, was observed between R-FSS 
and overall CIS scores in both CIDP (r=0.685, p=<0.001) and CMT patients (r=0.897, p=<0.001). Of the 
CIS subdomains, R-FSS showed positive linear correlation with subjective feeling of fatigue (r=0.793, 




p<0.001), motivation (r=0.423, p=0.031) and physical activity (r=0.679, p<0.001) in CIDP patients and 
with subjective feeling of fatigue (r=0.761, p=0.002), motivation (r=0.932, p<0.001) and physical 
activity (r=0.839, p<0.001) in CMT patients. 
6.5.1 Experienced fatigue and MUNIX 
No significant linear correlation was observed between peripheral motor unit function, assessed 
using MUNIX and MUSIX values, and experienced fatigue, assessed using R-FSS and overall CIS scores 
(see Tables 7 and 8).  
Physiological fatigue, defined as reduction in force of grip strength during 1 minute of maximal 
contraction, showed positive correlation with R-FSS (r=0.439, p=0.025) and overall CIS scores 
(r=0.486, p=0.012) in CIDP patients but not in CMT patients.  
In CIDP patients, overall CIS scores showed significant correlations with clinical assessments of motor 
and sensory function, including MRC muscle strength sum scores (r=-0.413, p=0.036), grip strength 
(r=-0.544, p=0.004), INCAT sensory sum scores (r=0.507, p=0.008) and vibration thresholds (r=-0.497, 
p=0.010). R-FSS scores correlated with grip strength (r=-0.476, p=0.014) and vibration thresholds (r=-
0.504, p=0.009) but not MRC muscle strength sum scores or INCAT sensory sum scores.  
In CMT patients, both R-FSS and overall CIS scores correlated with grip strength (R-FSS r=-0.534, 
p=0.041; CIS r=-0.518, p=0.048). No significant linear correlation was observed with other clinical 
assessments of motor or sensory function. 
R-FSS and overall CIS scores also showed significant linear correlation with overall disease severity 
scores in CIDP patients, assessed using R-ODS (R-FSS r=-0.588, p=0.003; CIS r=-0.641, p<0.001) and 
ONLS (R-FSS r=0.426, p=0.030; CIS r=0.543, p=0.004). In CMT patients, experienced fatigue scores 
correlated with R-ODS (R-FSS r=-0.583, p=0.029; CIS r=-0.699, p=0.009) but not ONLS scores. R-FSS 
and overall CIS scores correlated with both depression (R-FSS r= 0.536, p=0.005; CIS r=0.704, 
p<0.001) and anxiety (R-FSS r=0.428, p=0.029; CIS r=0.553, p=0.003) scores in CIDP patients, but not 
in CMT patients.  
Finally, significant linear correlation was observed between R-FSS and overall CIS scores with both  
physical components sum scores (R-FSS r=-0.425, p=0.030; CIS r=-0.518, p=0.007) and mental 
components sum scores (R-FSS r=-0.457, p=0.019; CIS r=-0.691, p=0.001) of SF-36 in CIDP patients. In 
CMT patients, experienced fatigue scores correlated with physical components sum scores of SF-36 
(R-FSS r=-0.757, p=0.002; CIS r=-0.804, p=0.001) but not mental components sum scores. In the 
study of Merkies et al55, validity of the FSS was demonstrated by correlation with the vitality domain 




of the SF-36. Both the R-FSS and CIS showed significant correlation with this subscale in CIDP and 
CMT patients. Full details of correlation analysis, including correlations between experienced fatigue 
scores and other relevant data are provided in Tables 7 and 8. 
Multivariate stepwise linear regression modelling was performed in the CIDP patient group, 
including potential explanatory variables that demonstrated significant linear correlation in the 
univariate analysis. Separate modelling was performed using R-FSS and overall CIS score as the 
outcome variable. Included variables were clinical markers of motor function (MRC muscle strength 
sum scores and grip strength), clinical markers of sensory function (INCAT sensory sum score or 
vibration thresholds) HADS depression score, HADS anxiety score and physiological fatigue (decline 
in grip strength during a 1-minute fatiguing contraction). INCAT sensory sum score and vibration 
thresholds both assess sensory function and demonstrate significant collinearity. Therefore, only the 
method demonstrating strongest correlation with the outcome variable in the univariate analysis 
was included.   
Using R-FSS score as the outcome variable the model identified 2 variables significantly contributing 
to experienced fatigue; HADS depression score (B=0.659 (95% CI 0.15-1.16), p=0.013) and Grip 
strength (B=-0.155 (95% CI -0.28--0.03), p=0.018). R2 was 0.445 and f-score was 9.24 (p=0.001), 
indicating the relationship between the explanatory variables and outcome variable was significant.  
Using overall CIS score as the outcome variable the model identified the same 2 explanatory 
variables; HADS depression score (B=4.550 (95% CI 2.66-6.44), p<0.001) and Grip strength (B=-0.724 
(95% CI -1.19--0.26), p=0.004). R2 was 0.667 and f-score was 23.04 (p<0.001).  The following 
regression equations were calculated: 
R-FSS=15.45+0.659(HADS depression score)-0.155(Grip strength) 
Overall CIS=70.52+4.55(HADS depression score)-0.724(Grip strength)  















Age -0.163 0.425 0.38-0.86 -0.077 0.710 -0.47-0.36 
Time since diagnosis 0.186 0.363 -0.19-0.56 -0.077 0.708 -0.44-0.36 
       
MUNIX -0.330 0.100 -0.66-0.14 -0.319 0.113 -0.64-0.11 
MUSIX 0.073 0.721 -0.38-0.54 0.004 0.984 -0.40-0.47 
Physiological fatigue 0.439 0.025 0.14-0.64 0.486 0.012 0.14-0.69 
       
MRC sumscores -0.238 0.242 -0.65-0.19 -0.413 0.036 -0.72--0.22 
Grip strength -0.476 0.014 -0.77--0.06 -0.544 0.004 -0.81--0.19 
       
INCAT sensory sumscore 0.339 0.090 -0.10-0.68 0.507 0.008 0.17-0.74 
Vibration thresholds -0.504 0.009 -0.78--0.11 -0.497 0.010 -0.75--0.20 
       
R-ODS -0.558 0.003 -0.81--0.17 -0.641 <0.001 -0.81--0.35 
ONLS 0.426 0.030 -0.01-0.73 0.534 0.004 0.15-0.81 
       
HADS depression 0.536 0.005 0.08-0.82 0.704 <0.001 0.40-0.87 
HADS anxiety 0.428 0.029 0.05-0.72 0.553 0.003 0.22-0.79 
       
SF-36        
Physical functioning NBS -0.487 0.012 -0.77--0.06 -0.643 <0.001 -0.86--0.29 
Role physical NBS -0.380 0.055 -0.72-0.07 -0.592 0.001 -0.82--0.24 
Bodily pain NBS -0.289 0.152 -0.62-0.16 -0.259 0.202 -0.62-0.17 
General health NBS -0.454 0.020 -0.73--0.04 -0.590 0.002 -0.84--0.20 
Vitality NBS -0.596 0.001 -0.82--0.26 -0.881 <0.001 -0.97--0.69 
Social functioning NBS -0.708 <0.001 -0.89--0.38 -0.679 <0.001 -0.83--0.42 
Role emotional NBS -0.488 0.011 -0.75--0.14 -0.647 <0.001 -0.82--0.34 
Mental health NBS -0.208 0.307 -0.59-0.25 -0.521 0.006 -0.80--0.13 
Physical components 
sumscore NBS 
-0.425 0.030 -0.71--0.01 -0.518 0.007 -0.79--0.01 
Mental components 
sumscore NBS 
-0.457 0.019 -0.75--0.04 -0.619 0.001 -0.85--0.25 
Table 7: Linear correlation analysis of experienced fatigue assessments in patients with CIDP. 
Experienced fatigue assessed using both the Rasch-built fatigue severity scale and the Checklist of 
Individual Strength. Significant correlations are highlighted in bold. 
 















Age 0.352 0.198 -0.02-0.22 0.344 0.209 -0.25-0.57 
       
MUNIX -0.105 0.721 -0.62-0.47 -0.115 0.696 -0.63-0.43 
MUSIX -0.473 0.088 -0.81-0.12 -0.474 0.087 -0.85-0.16 
Physiological fatigue 0.331 0.320 -0.41-0.81 0.091 0.790 -0.63-0.67 
       
MRC sumscores -0.181 0.519 -0.61-0.39 -0.103 0.714 -0.61-0.46 
Grip strength -0.534 0.041 -0.83--0.03 -0.518 0.048 -0.82--0.02 
       
INCAT sensory sumscore -0.338 0.218 -0.18-0.78 0.434 0.106 -0.12-0.89 
Vibration thresholds -0.241 0.387 -0.75-0.33 -0.156 0.578 -0.75-0.37 
       
R-ODS -0.583 0.029 -0.88-0.07 -0.669 0.009 -0.89--0.13 
ONLS 0.221 0.447 -0.37-0.72 0.221 0.448 -0.30-0.67 
       
HADS depression 0.223 0.444 -0.42-0.83 0.257 0.376 -0.39-0.87 
HADS anxiety -0.138 0.638 -0.65-0.45 -0.139 0.636 -0.69-0.50 
       
SF-36        
Physical functioning NBS -0.729 0.003 -0.92--0.20 -0.709 0.004 -0.93--0.22 
Role physical NBS -0.761 0.002 -0.93--0.34 -0.799 0.001 -0.95--0.45 
Bodily pain NBS -0.141 0.630 -0.67-0.51 0.069 0.814 -0.50-0.59 
General health NBS -0.380 0.180 -0.73-0.30 -0.471 0.089 -0.82-0.12 
Vitality NBS -0.861 <0.001 -0.97-0.57 -0.889 <0.001 -0.98--0.61 
Social functioning NBS -0.336 0.241 -0.80-0.29 -0.459 0.099 -0.92-0.14 
Role emotional NBS -0.164 0.576 -0.75-0.47 -0.012 0.967 -0.57-0.60 
Mental health NBS -0.037 0.900 -0.66-0.58 0.052 0.860 -0.52-0.58 
Physical components 
sumscore NBS 
-0.757 0.002 -0.94--0.30 -0.804 0.001 -0.96--0.42 
Mental components 
sumscore NBS 
-0.136 0.643 -0.70-0.47 -0.018 0.952 -0.57-0.55 
Table 8: Linear correlation analysis of experienced fatigue assessments in patients with CMT. 
Experienced fatigue assessed using both the Rasch-built fatigue severity scale and the Checklist of 
Individual Strength. Significant correlations are highlighted in bold. 









Figure 9: CIDP patients. Correlation between variables included in the multivariate linear regression models. A) 
R-FSS score and HADS depression scores, R2=0.29, Spearman Rank correlation coefficient 0.54 (p=0.005). B) R-
FSS score and grip strength assessed using a Jamar-grip dynamometer, R2=0.27, Spearman Rank correlation 
coefficient -0.48 (p=0.014). C) Overall CIS score and HADS depression scores, R2=0.52, Spearman Rank 
correlation coefficient 0.70 (p<0.001). D) Overall CIS score and grip strength assessed using a Jamar-grip 
dynamometer, R2=0.31, Spearman Rank correlation coefficient -0.54 (p=0.004). Graph shows best-fit line and 
95% confidence band of best-fit line. 




6.6 Assessment following intravenous immunoglobulin treatment in chronic 
inflammatory demyelinating polyneuropathy  
Repeat assessments were performed in 20 CIDP patients; 15 receiving regular maintenance IVIg and 
5 receiving physiotherapy only.  Patients receiving IVIg therapy were seen immediately before an 
infusion and on average 15 days after the same IVIg infusion. Significant improvements were seen in 
MRC muscle strength sum scores (mean value 67.5 to 69.4, p=0.033) and 10m walk time (mean 
value 13.2s to 11.4s, p=0.044). There was a trend towards improvement in R-ODS, which didn’t 
reach statistical significance (mean value 53.3 to 55.2, p=0.085). In comparison, a small 
improvement in 10m walk time was found in 5 untreated patients participating in ongoing 
physiotherapy between appointments (mean value 9.7s to 9.3s, p=0.017), but no improvement was 
observed in other clinical assessments in this group. 
Significant improvements were seen in MUNIX sum scores (mean value 188.3 to 226.4, p=0.001) but 
not MUSIX sum scores (mean value 266.5 to 253.5, p=0.312) following IVIg therapy. There was no 
significant change in MUNIX sum scores on repeat assessment in untreated patients (see Figure 10). 
In addition to MUNIX sum scores, small but significant improvement was seen following IVIg therapy 
in DML (median value 6.4 to 6.1, p=0.022), amplitude of the distal-evoked CMAP (median value 5.0 
to 5.7, p=0.035), duration of the proximal-evoked CMAP (median value 8.7 to 7.5, p=0.046) and 
persistence of the F-wave (median value 25 to 33.8, p=0.014). No significant changes were seen in 
any of the other electrophysiological parameters (Full details provide in Table 9). 
No changes were seen in CIS scores, including subscales over repeat appointments in both patient 
groups. A small but statistically significant reduction in R-FSS scores were seen in CIDP patients 
receiving IVIg therapy (median value 17 to 15, p=0.037).  
 CIDP patients IVIg group (n=15) CIDP patients no IVIg group (n=5) 
 Baseline Follow-up p-value Baseline Follow-up p-value 
MRC 67.5 (10.0) 69.4 (10.3) 0.033 71.0 (9.4) 71.4 (10.0) 0.648 
Grip strength (kg) 23.7 (12.7) 24.8 (11.0) 0.332 28.4 (10.0) 29.4 (13.1) 0.616 
       
INCAT 8.3 (4.9) 7.9 (5.5) 0.661 5.4 (1.5) 5.8 (1.3) 0.621 
Vibration 23.9 (10.9) 25.0 (11.1) 0.503 33.4 (6.8) 30.6 (7.7) 0.300 
       
10m walk time (s) 13.2 (6.8) 11.4 (4.2) 0.044 9.7 (2.1) 9.3 (1.9) 0.017 
R-ODS 53.2 (19.6) 55.2 (21.8) 0.085 59.6 (10.1) 58.4 (10.5) 0.208 
ONLS 4.5 (2.0) 4.3 (2.1) 0.051 2.8 (2.1) 2.8 (2.1) - 




       
R-FSS 17 (14-19.5)* 16 (11.5-17.5)* 0.054 16 (15-19)* 16 (16-17)* 1.000 
CIS overall 75 (66.5-104)* 79 (63.5-94)* 0.232 90 (87-94)* 95 (82-100)* 1.000 
CIS subjective 40 (33-45)* 39 (35-49)* 0.906 40 (38-52)* 40 (39-45)* 0.285 
CIS concentration 14 (8-19.5)* 14 (8-17.5)* 0.502 16 (15-24)* 22 (14-22)* 0.593 
CIS motivation 15 (11-16.5)* 13 (8.5-15)* 0.061 14 (13-20)* 20 (14-21)* 0.593 
CIS physical activity 16 (8.5-19)* 12 (9.5-16.5)* 0.161 9 (8-16)* 14 (8-14)* 1.000 
       
MUNIX sumscore 188.3 (110.5) 226.4 (132) 0.001 264 (150.4) 256.6 (168.7) 0.684 
MUSIX sumscore 266.5 (84.7) 253.5 (99.9) 0.312 271 (161.8) 270.7 (136.7) 0.952 
       
Physiological fatigue (%) 49.7 (44.3-53.2)* 41.9 (31.4-50.0)* 0.233 51.1 (32.4-62.2)* 46.5 (38.4-62.2)* 0.715 
Decline in RMS (%) 17.2 (-9.9-33.1)* 2.75 (-9.2-19.3)* 0.363 37.0 (20.2-39.9)* 24.7 (8.9-37.0)* 0.686 
RMS in submaximal 
contraction (%) 
48.4 (41.6-60.4)* 42.3 (37.1-48.2)* 0.221 31.0 (28.0-47.5)* 44.7 (31.1-47.5)* 0.285 
       
Motor nerve conduction studies 
DML (ms) 6.4 (5.2-6.9)* 6.1 (4.9-7.2)* 0.022 4.6 (3.7-6.1)* 4.8 (4.4-5.7)* 0.500 
dCMAP amplitude (mV) 5.0 (3.1-5.6)* 5.7 (3.7-6.2)* 0.035 5.5 (4.3-5.6)* 5.6 (4.8-5.8)* 0.138 
dCMAP area (mV*ms) 13.8 (7.1) 14.2 (6.2) 0.903 13.8 (4.5) 13.9 (4.1) 0.802 
dCMAP duration (ms) 7.5 (6.7-10.0)* 7.7 (6.5-10.2)* 0.552 7.6 (6.9-7.8)* 6.1 (5.3-8.4)* 0.345 
pCMAP amplitude (mV) 4.6 (1.4-5.2)* 4.3 (1.6-5.6)* 0.485 5.5 (4.7-5.6)* 5.8 (5.5-5.9)* 0.080 
pCMAP area (mV*ms) 13.9 (9.9) 13.8 (8.8) 0.984 15.1 (7.2) 15.8 (6.2) 0.583 
pCMAP duration (ms) 8.7 (7.1-13.3)* 7.5 (6.4-8.8)* 0.046 6.7 (6.1-7.0)* 6.0 (5.6-6.4)* 0.080 
MNCV (m/s) 36.1 (25.5-41.6)* 37.8 (27.3-40.2)* 0.117 30.2 (29.8-32.2)* 31.7 (28.6-35.9)* 0.686 
F-wave latency (ms) 47.5 (10.3) 44.3 (8.3) 0.079 36.4 (7.0) 32.3 (1.8) 0.242 
F-wave persistence (%) 45 (35.8-60.0)* 70.0 (55.0-81.3)* 0.021 25 (20-42.5)* 35 (0-47.5)* 0.786 
       
Sensory nerve conduction studies  
SNAP amplitude (µV) 3.2 (0.8-4.5)* 3.3 (1.0-6.0)* 0.062 3.7 (2.5-4.3)* 1.5 (1.1-2.7)* 0.066 
SNCV (m/s) 30.0 (9.8-37.6)* 30.5 (12.9-40.7)* 0.272 49.6 (32.4-53.4)* 34.7 (19.7-47.5)* 0.063 
Table 9: Repeat assessments performed in CIDP patients receiving IVIg therapy and CIDP patients not 
receiving IVIg therapy. *Data presented as median values (IQR). Otherwise data presented as mean 
values (SD). Differences assessed using paired two-tailed student t-test or Wilcoxon Signed Ranks 
test. Significant differences highlighted in bold. 




Figure 10: Scatterplots demonstrating changes in MUNIX and MUSIX sumscores between repeat 
appointments in CIDP patients receiving regular IVIg infusions (n=15) and patients not receiving 
active treatment (n=5). Changes in values within patient groups assessed using paired, 2-tail student 
t-test. 




7. Discussion  
7.1 Relationship between experienced fatigue, physiological fatigue and peripheral nerve 
function in patients with acquired and hereditary demyelinating peripheral neuropathy.  
In this study, MUNIX technique was used as a marker for number of functioning motor units. MUNIX 
sum scores were significantly lower in both CMT and CIDP patients compared to healthy controls. 
Interestingly, whilst mean MUSIX sum scores were higher in both patient groups, there was 
considerable overlap with values recorded in controls, with some patients having lower MUSIX sum 
scores than controls.  During chronic and progressive loss of motor neurones, surviving motor 
neurones sprout collateral terminal axon branches to re-innervate denervated muscle fibres within 
their motor unit territory. As a result, there is an increase in “size” of the surviving motor units. In 
the context of the MUNIX calculation, this means that each surviving motor unit has a greater overall 
contribution to the summated muscle action potential (the CMAP). Given that low MUNIX sum 
scores were observed in some patients without corresponding increase in MUSIX sum scores, a 
possible mechanism could be motor conduction block or conduction failure due to nodal/paranodal 
dysfunction. In both CMT and CIDP patients, the lowest MUSIX sum scores correlated with the 
lowest MUNIX sum scores and low amplitude CMAP potentials. It is also possible that low MUSIX 
sum scores could result from severe loss of motor units, with insufficient surviving motor neurones 
to allow reinnervation to occur. These various mechanisms likely explain the greater variation in 
MUSIX sum scores seen in patients with CMT and CIDP compared to controls.  
Physiological fatigue was assessed using continuous grip strength measurements. CMT and CIDP 
patients demonstrated reduced grip strength at baseline compared to controls. In addition, CMT 
patients showed slower decline in force of grip strength during a fatiguing task. No difference was 
observed comparing decline in grip strength during 1 minute of continuous forearm muscle 
contraction in CIDP patients and controls.  
MUNIX studies suggest patients with CMT and CIDP have fewer functioning peripheral motor 
neurones than healthy controls. It was therefore hypothesised that a greater proportion of available 
motor neurones would be activated during submaximal muscle contraction in patients compared to 
controls. To test this hypothesis, RMS of the rectified SEMG signal recorded from forearm flexor 
muscles was measured during the fatiguing muscle contraction. For the purpose of this study, SEMG 
was used as a surrogate marker for neural activation. There was a greater decline in this signal in 
controls than in both CMT and CIDP patients. The ratio of RMS of the SEMG signal during maximal 
and submaximal hand grip was also calculated. As predicted, the ratio was lower in both CIDP and 
CMT patients compared to controls (not reaching statistical significance in the CMT patient group, 




although as only 11 patients completed this part of the assessment, this may be due to small sample 
size). Furthermore, a negative linear correlation was observed between MUNIX values and ratio of 
RMS of the SEMG during maximal and submaximal contraction.  
In combination, these finding support the hypothesis that patients with lower number of functional 
motor units have altered patterns of neural activation, requiring similar neural activation to maintain 
a submaximal forearm muscle contraction as to maintain a maximal forearm muscle contraction.  It 
can be hypothesised that constant activation of a greater proportion of the available motor unit pool 
during routine motor tasks could lead to earlier fatigue. However, there are several inconsistencies 
which should be addressed. Some authors have suggested there is greater relative drop-out of 
motor neurones in patients with peripheral neuropathy during a fatiguing task71,87. However, in this 
study, no difference was observed in development of physiological fatigue between controls and 
CIDP patients, and decline in power of the SEMG signal was slower in patients than controls. Whilst 
physiological fatigue may result from reduced neural activation, local factors will also be involved, 
such as production of lactic acid during exercise110,111. Greater peripheral fatigue in controls 
compared to patients with peripheral neuropathy is hypothesised to occur because patients are 
unable to generate maximal muscle contraction, resulting in less anaerobic respiration and lower 
production of lactic acid71. The balance between these two factors, local peripheral fatigue and 
neural activation, will affect development of physiological fatigue and may explain the observed 
inconsistencies in this study71,82,87.  
Two self-report scales are used to assess experienced fatigue in this study. A strong correlation is 
demonstrated between these scales in patients with CMT and CIDP. In addition, both scales show 
strong correlation with the vitality domain of the SF-36 questionnaire, which has been used to 
validate fatigue scales in previous studies in similar patient groups55. These findings suggest that 
both scales are valid methods of assessing experienced fatigue in these patient groups. It must also 
be acknowledged that there is some variation when scores are compared between groups. For 
example, median R-FSS scores were higher in CIDP patients than CMT patients, but median overall 
CIS scores were lower.  The FSS (from which the R-FSS is adapted) assesses impact of fatigue on 
types of daily activity, whereas the multidimensional CIS aims to assess severity of fatigue 
symptoms. It is possible that patients with CMT may experience more severe symptoms of fatigue, 
but owing to CMT being a hereditary disorder, be less conscious of the daily impact of fatigue. 
No significant correlation was observed between experienced fatigue and MUNIX or MUSIX sum 
scores in either patient group. In CIDP patients, a weak positive correlation was observed between 
experienced fatigue levels and decline in grip strength during a fatiguing contraction. However, the 




only two variables to contribute to experienced fatigue in regression analysis were depression scores 
and maximal grip strength. Analysis using both R-FSS scores and overall CIS scores as outcome 
variables identified the same two explanatory variables, again increasing confidence in the validity of 
these assessment scales. This finding indicates experienced fatigue is likely to be multifactorial in 
patients with CIDP, related to markers of physical impairment and psychological factors, most 
importantly co-morbid depression. It is also worth noting that the regression modelling explained 
only 44.5% and 66.7% of the variance in R-FSS and overall CIS scores, respectively. Therefore, a 
significant proportion of the variance is unexplained by the explanatory variables included in this 
study. In CMT patients, the only explanatory variable found to correlate with experienced fatigue 
scores was grip strength. For this reason, and due to the smaller sample size, regression modelling 
could not be performed in CMT patients. In contrast to CIDP patients, depression scores showed no 
correlation with experienced fatigue level in CMT patients. 
In recovered patients with GBS, Drenthen et al59 found that only the number of functioning 
peripheral motor units explained residual fatigue levels, assessed using motor unit number 
estimation. No similar relationship was found in CIDP patients in this study. This may reflect a 
different method for assessing peripheral motor unit function. However, Furtula et al139 have shown 
similar diagnostic accuracy of MUNIX and intermittent stimulation-MUNE in patients with 
amyotrophic lateral sclerosis, but suggest that due to lower intra-rater variability MUNIX technique 
is superior.  An alternative explanation for the difference between these findings and those reported 
by Drenthen et al may be different pathophysiological mechanisms of fatigue in subacute and 
chronic peripheral neuropathies. 
Menotti and colleagues96 suggest fatigue experienced by patients with CMT is related to high 
activation of cognitive association areas in the prefrontal cortex during routine motor tasks. This is 
considered to be a compensatory mechanism for reduced activation of peripheral motor units. This 
study demonstrates both lower number of functional motor units in patients with CIDP and CMT and 
differences in neural activation during a physical fatiguing task compared to controls. However, 
assessment of number of functioning peripheral motor units did not correlate significantly with 
experienced fatigue in this study. Whilst peripheral motor unit dysfunction may play a role in 
experienced fatigue, this does not appear to be the strongest predictor in our study, suggesting 
other factors are more important. 
Several studies report fatigue negatively correlates with quality of life scores in patients with CIDP 
and CMT55,72,83,90,92. Similar relationships were found in this study. Both patient groups scored lower 
in the physical components subscale of the SF-36 compared to a population drawn from the general 




UK population. In addition, experienced fatigue levels showed strong negative correlation with the 
physical functioning and role physical domains of the SF-36 in both patient groups. Experienced 
fatigue correlated with the mental components subscale of the SF-36 and depression and anxiety 
scores in patients with CIDP. Similar relationships were not observed in patients with CMT, however.  
7.2 MUNIX technique 
MUNIX was first proposed as a method of monitoring loss of motor units in patients with 
amyotrophic lateral sclerosis (ALS)126,127. Good intra- and inter-rater reproducibility of MUNIX and 
MUSIX has been demonstrated in healthy controls and in ALS138,141–145. More recently, a multicentre 
study has suggested training in the technique improves reliability for the purpose of large-scale 
clinical trials146.  
In this study, preliminary collection of normal MUNIX data was performed in healthy controls to 
assess test-retest intra-rater reliability.  Care was taken to ensure standardisation of the technique 
across repeat tests. Standard electrode positioning was used, as detailed in section 4.2.3.  Signals 
acquired at low force levels appear to disproportionately affect MUNIX values and these epochs 
were carefully reviewed for artefact, with epochs where SIP area was lower than CMAP area 
excluded128,147. In addition, SIP epochs with an area of <20mV/ms or ICMUC > 100 were excluded. 
demonstrated good test-retest reliability, which was similar to previous reports using this 
technique130,138,141–145. Good test-retest reliability was demonstrated, with maximum variance of 
21.4%, which was similar to previous reports using this technique130,138,141–145. This suggests that the 
methods used for acquiring MUNIX and MUSIX values in this study are valid for assessing 
longitudinal changes in patients. 
Whilst similar variance was observed in sum scores calculated from 3 muscles, variance in MUNIX 
and MUSIX scores from TA was, however, greater than some previous reports130. This may result 
from placement of the reference electrode, with other authors utilising placement over the patella 
tendon135.  Alternatively, this may reflect the method used for placement of the active (recording) 
electrode on repeat testing.  During this study care was taken to ensure optimal electrode 
positioning by repositioning the active electrode for multiple stimulations until maximum amplitude 
CMAP was acquired. Reference electrode position was maintained according to the anatomical 
landmarks outlined previously. Supporting this approach, original descriptions of the MUNIX 
technique found that accuracy is dependent upon acquiring a maximum amplitude CMAP128,141.  It 
was therefore felt important to achieve a maximal CMAP for each test. However, other authors have 
suggested maintaining active electrode positioning according to anatomical landmarks improves 
test-retest reliability (unpublished observation). This can be achieved by placing electrodes at fixed 




distances from anatomical landmarks or photographing electrode placement for reference on repeat 
testing. It is possible that adopting this technique may improve retest reliability for large muscles 
such as tibialis anterior, where there is potential for greater variation in electrode placement. 
Muscle selection was based on previous studies published in similar patient groups130,137,148. Whilst 
small muscles of the feet, such as extensor digitorum brevis, can be studied with MUNIX technique, 
this was avoided in this study. The majority of patients with chronic peripheral neuropathies 
demonstrate significant if not complete atrophy of distal muscles in the lower limbs, preventing 
accurate calculation of MUNIX values. 
MUNIX and MUSIX do not provide a measure of the actual number or size of motor units, instead 
providing an index value accurately related to these parameters.  Therefore, whilst technically not a 
technique for motor unit estimation, MUNIX was developed to track motor unit function over time. 
It has the advantage of being quicker and easier to perform and better tolerated by patients than 
techniques for motor unit estimation (MUNE)127,149. Initial studies suggest MUNIX is strongly 
correlated and non-inferior to incremental stimulation and high-density MUNE techniques136,139. It 
has been suggested that a very recently developed technique, MScan MUNE is more accurate at 
differentiating between controls and patients with ALS than MUNIX or more traditional multi-point 
stimulation MUNE techniques150. It was also observed that MUNIX showed slightly higher correlation 
with CMAP amplitude than other MUNE techniques, leading some authors to suggest CMAP 
amplitude has a greater influence on MUNIX and MUSIX than number or size of functioning motor 
units151,152. However, in this study MUNIX sum scores showed greater correlation with clinical data in 
both CIDP and CMT patients than distally-evoked CMAP amplitude. This finding is consistent with 
previous reports in CIDP130, and indicates that despite criticism outlined above, MUNIX provides 
additional clinically-relevant information regarding motor unit function not available from analysis of 
the CMAP. 
7.3 Relationship between MUNIX and MUSIX sum scores and clinical assessments in patients 
with CIDP and CMT 
MUNIX sum scores correlated with clinical measures of motor function and disability scores in 
patients with CIDP. MUNIX sum scores showed a significant correlation with both grip strength and 
muscle strength assessed by MRC sum scores. MUNIX assessments were performed in distal muscles 
of upper and lower limbs. MRC sum scores incorporated clinical assessments of proximal and distal 
muscle strength. Despite this, significant correlations were observed between the two assessments. 
They also correlated with self-reported disability level, with patients with lower MUNIX sum scores 
experiencing higher disability levels. These findings are similar to previous reports130. In addition, 




there was significant correlation between MUNIX sum scores and clinical measures of sensory 
function, which has not previously been reported.  In contrast, MUSIX sum scores correlated with 
patient age but none of the clinical assessments.  
In CMT patients, MUNIX sum scores also showed significant correlation with clinical assessments of 
motor function (MRC muscle strength sum scores and grip strength), 10 metre timed walk and one 
disability scale (ONLS). These findings are consistent with previous reports in this patient 
population153. In addition, MUNIX sum scores also showed significant correlation with clinical 
measures of sensory function and patient age. MUSIX sum scores did not correlate with any of the 
clinical assessments. 
As mentioned previously, MUNIX is used to assess the number of functioning motor units. It is 
therefore intuitive that patients with lower MUNIX values would present with greater weakness and 
higher perceived level of disability. Whilst not directly assessing sensory nerve function, the 
correlation between MUNIX sum scores and clinical measures of sensory function in both patient 
groups is likely to reflect overall disease severity. Such associations have been found previously with 
levels of sensory dysfunction in CIDP154. 
MUNIX sum scores showed greater correlation with clinical assessments and disability scores than 
MUSIX sum scores.  This suggests that the number of functioning motor units, rather than chronic 
motor unit re-innervation, contributes more to motor impairments and overall disability in these 
patient groups. As mentioned earlier, some authors have criticised MUNIX as an index of CMAP 
amplitude rather than number of functioning peripheral motor units152. However, in this study 
MUNIX sum scores are demonstrated to correlate with markers of motor and sensory function and 
validated disability scales. Similar correlations were not seen with distal-evoked CMAP amplitudes in 
either CIDP or CMT patients, indicating that MUNIX provided clinically relevant information not 
available from analysis of the CMAP amplitude alone.  In CMT patients, proximal-evoked CMAP 
amplitude and area showed similar correlations with clinical assessments and disability scores.  In 
CIDP patients, stronger correlations were observed with MUNIX sum scores than any of the other 
electrophysiological parameters. Interestingly, of the other electrophysiological parameters studied, 
only F-wave persistence showed modest correlation with both muscle strength assessments and 
disability scores. In CIDP, there is usually predominant involvement of nerve roots and proximal 
nerve segments. F-waves can be used to indirectly assess proximal nerve segments, which may 
explain this finding. 
7.4 Short-term changes in clinical and electrophysiological assessments after treatment in 
patients with chronic demyelinating polyneuropathy  




Short-term improvement was seen in MUNIX sum scores comparing studies performed immediately 
before and 2 weeks following IVIg therapy. Conversely, no significant change in MUNIX sum scores 
was seen on repeat testing in a small group of untreated patients. In contrast to previous studies, no 
significant change in averaged proximally-evoked CMAP amplitude was detected. Small 
improvements were seen in averaged distal motor latency, amplitude of the distally-evoked CMAP, 
duration of the proximally-evoked CMAP and persistence of the f-wave. 
Previous authors have suggested a minimum clinically relevant change in MUNIX sum scores of 50% 
in CIDP130, based on the maximum variation seen in stable patients receiving IVIg therapy. The 
maximum change in MUNIX sum scores observed on repeat testing in controls was 21.4% and in 
untreated patients (albeit in a small cohort) was 32.9%. This suggests a smaller change in MUNIX 
sum scores may be clinically relevant. Whilst this study was not designed to determine minimum 
clinically significant changes, based on our findings in healthy controls and previous reports of 
variance in MUNIX values, a change in MUNIX values of 25% could be considered clinically 
significant.  A small improvement in muscle strength was also observed and mean values in self-
reported disability were higher following IVIg therapy, but failed to reach statistical significance. This 
was despite recruitment of clinically stable patients, reflecting the well-reported “wearing off effect” 
of IVIg therapy observed in CIDP28,29. 
Lower MUNIX values observed in CIDP have been attributed to chronic axonal loss137.  Higher MUSIX 
values were observed in some CIDP patients compared with controls, suggesting motor unit 
remodelling related to chronic axonal loss in some of our patient cohort. However, the improvement 
in MUNIX values following IVIg appears too rapid to be explained by axonal regeneration or even 
nerve remyelination. Similar observations have been made regarding functional improvements 
following IVIg therapy in CIDP155. Nerve excitability studies in CIDP suggest disruption of nodal 
sodium-channel function and resulting hyperpolarisation may interfere with nerve conduction and 
cause block156–159. Elevated thresholds on nerve excitability studies have also been demonstrated in 
CIDP patients with and without conduction block compared to healthy controls, possibly related to 
changes in the paranodal region160. Although autoantibodies are only identified in a minority of 
patients26, it is hypothesized that IVIg competes with functionally important autoantibodies, 
producing rapid although reversible improvement in nodal function155,158. It is possible the observed 
improvements in MUNIX values result from functional axonal recovery due to improved nodal 
function after IVIg therapy. Given that motor unit size relates to motor unit remodelling in 
association with gradual, chronic axonal loss, it is unsurprising that no significant change in MUSIX 
values was observed on repeat testing over a short interval. However, a large improvement in 




MUSIX sum score was observed in a single patient. This patient had one of the lowest MUNIX values 
in the study cohort and although it is difficult to make hypotheses based on a single observation, it is 
possible the increase in MUSIX reflected presence of large motor units that were “non-functioning” 
at the time of assessment prior to IVIg therapy. 
7.5 Short-term changes in fatigue levels and how these correlate with clinical and 
electrophysiological assessments after treatment in patients with chronic demyelinating 
polyneuropathy 
Short-term fluctuations were explored in CIDP patients by performing assessments immediately 
before an IVIg infusion and on average 2 weeks later. This methodology was designed to explore the 
well-reported “wearing-off effect” of treatment observed with IVIg28,29, which requires repeat 
infusions at 2 to 6 week intervals32,33,35 to maintain therapeutic benefit in around 65% of patients30. 
This study design allowed recruitment of a reasonable sample size from a single centre, which would 
not have been possible if recruiting newly-diagnosed and treatment naïve patients, given the low 
incidence of CIDP. Owing to this methodology, it should be recognised that patients receiving IVIg 
therapy recruited to this study would have had their dosing regimen carefully titrated to achieve 
clinical stability.  
It is therefore perhaps unsurprising that no significant changes were observed in assessments of 
disability or experienced fatigue levels on repeat assessment. In addition, no significant changes 
were seen in any of the parameters used to assess physiological fatigue. Previous authors have 
suggested assessment of physiological fatigue has modest test-retest reliability82. Large variation 
was observed on repeat assessment of SEMG activity from forearm flexor muscles, even in the 
untreated CIDP patient group, suggesting this methodology may not be suitable to track changes in 
neural activation over time. 
As described above, a significant improvement in MUNIX sum scores was observed, along with small 
but statistically significant improvements in MRC muscle strength sum scores and 10-metre walk 
time. This finding suggests that MUNIX sum scores may be highly sensitive to fluctuations in 
peripheral motor unit function in CIDP. The fact that significant changes were observed in MUNIX 
sum scores without corresponding changes in fatigue levels again suggests there is no simple 
relationship between peripheral motor unit function and experienced fatigue in this patient group. 
7.6 Limitations 
Several limitations of this study need to be addressed. Firstly, only 15 patients with CMT were 
successfully recruited, whereas a sample size calculation had suggested a sample size of 17 was 




required to detect whether correlation between different variables differs from 0. In addition, only 
11 CMT patients completed the physiological fatigue component of the study. Therefore, whilst 
significant correlation between experienced fatigue levels and grip strength was demonstrated in 
this patient group, it cannot be concluded that the other variables under exploration did not 
correlate with experienced fatigue, only that this study was unable to find a correlation.   
A second potential criticism is the use of the Rasch-built fatigue severity scale and the Rasch-built 
overall disability scale in patients with CMT. Whilst R-ODS has been used to assess disability level in 
CMT patients153, these scales have been developed for use in patient with inflammatory 
polyneuropathies. MUNIX sum scores demonstrated significant correlation with ONLS, which has 
been validated in patients with CMT, but not R-ODS in this study.  R-ODS was used in both groups to 
create uniformity and allow direct comparison between groups. However, the use of a scale more 
commonly used in CMT populations, such as the CMT neuropathy score (CMTNS)52, may have 
allowed more detailed exploration of correlations between peripheral motor neuron function and 
disease severity. The CMTNS comprises scores based on severity of clinical symptoms, signs and 
electrophysiological parameters. On overall score reflecting disease severity is produced, which 
correlates well with other markers of disability161. In the CMTNS, sensory signs are assessed using a 
Rydell-Seiffer tuning fork and pinprick sensation. These modalities were assessed in this study as 
part of INCAT sensory sum scores and vibration thresholds. Similarly, motor symptoms in arms and 
legs were assessed as part of ONLS and R-ODS disability scores and motor signs were assessed with 
MRC sum scores. Finally, CMTNS incorporates ulnar nerve CMAP amplitudes and radial nerve SNAP 
amplitudes, again both assessed in this study. Therefore, whilst not using this specific scale, all 
individual components were assessed in this study and correlated with fatigue scores. In addition, 
some authors162 suggest that the CMTNS is not linearly-weighted and differentiates poorly between 
CMT patients with moderate disease severity, suggesting this scale may not be ideally suited to 
correlation analysis. 
A third potential limitation was the methodology for assessing physiological fatigue. Specifically, 
advanced techniques such as multi-electrode arrays that allow calculation of muscle-fibre 
conduction velocity, or twitch interpolation techniques, were not employed. Therefore, whilst SEMG 
recording was used as a surrogate marker for neural activation, the impact of local muscle fatigue on 
the SEMG signal is unknown. This means that it was not possible to determine contribution of 
central and peripheral fatigue on overall physiological fatigue71,87. However, the primary objective of 
this study was to explore the relationship between physiological fatigue and experienced fatigue in 




patients with demyelinating disorders of the peripheral nervous system. This objective is still 
achievable without further exploring factors contributing to physiological fatigue.  
Finally, control and patient groups were not age or sex-matched. Control data was collected to 
determine test-retest reliability of MUNIX and MUSIX sum scores. This data was also used to 
compare MUNIX data and physiological fatigue assessments between controls and patients. Controls 
were recruited on a convenience basis and were not age-matched to patients. Loss of motor units is 
recognised with advancing age163, which may have influenced the differences observed between 
patients and controls. However, MUNIX sum scores showed no correlation with age in CIDP patients. 
A greater proportion of CIDP patients included in this study were male, consistent with previously 
published epidemiological data23. In contrast, only 26% of the CMT cohort were male. However, 
previous studies utilising MUNE techniques have found no significant difference between number of 
motor units in APB and ADM muscles in healthy male and female subjects163. In addition, biological 
sex did not appear to be a predictive factor of experienced fatigue level in this study. Overall, whilst 
there was heterogeneity in demographic data between controls and patient groups, these 
observations indicate that this limitation would not significantly impact the overall findings of the 
study.  
8. Conclusion 
Fatigue in patients with chronic demyelinating disorders of the peripheral nervous system appears 
to be negatively correlated with quality of life.  Patients with both acquired and hereditary chronic 
demyelinating peripheral nerve disorders have reduced number of motor units assessed using 
MUNIX technique compared to control subjects. However, no clear relationship is found between 
number of functioning peripheral motor units and fatigue level experienced by patients. Depression 
and reduced grip strength were significant predictors of higher experienced fatigue levels in patients 
with chronic inflammatory demyelinating polyneuropathy. This suggests fatigue in this patient group 
is likely to be multifactorial, with physical and psychological contributors. However, the variables 
included in this study accounted for only 44.5 to 66.7% of the variation in experienced fatigue 
scores, suggesting that unidentified factors also contribute to experience of fatigue in this patient 
group. Differences in experienced fatigue levels and relationship with depression scores are 
observed between patients with CIDP and CMT1A, suggesting different factors are likely to 
contribute to fatigue in these patients. 
Differences in neural activation during fatiguing forearm muscle contraction are demonstrated 
between controls and patients with chronic peripheral neuropathies. Patients with lower MUNIX 
values were found to have similar surface EMG activation patterns during maximal and submaximal 




forearm muscle contraction. Based on this finding, it could be hypothesised that patients require a 
greater number of available motor units to be activated during routine motor tasks, which may 
contribute to fatigue. However, there are significant limitations with methods for assessing 
physiological fatigue and decline in force-generating capacity of forearm muscles over time did not 
correlate with experienced fatigue levels reported by patients. 
Although no relationship is demonstrated with fatigue, MUNIX sum scores correlate with measures 
of motor function and disability levels in patients with CIDP and CMT1A. Correlations with sensory 
function are also demonstrated. In addition, improvement in MUNIX values are demonstrated two 
weeks after IVIg therapy in clinically-stable CIDP patients on long-term treatment. This new finding 
suggests a potential role for MUNIX sum scores as an objective marker of response to IVIg therapy. 
IVIg availability and cost issues are of paramount importance in CIDP treatment and the limitations 
of motor and disability scores as sole monitoring tools are real and concerning in long-term patients 
in whom placebo effects are not uncommon. 
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Appendix 2: Patient information sheet 
RESEARCH PATIENT INFORMATION SHEET 
Study Title: Fatigue in Neuropathic Disorders (FIND Study) 
 
You are being invited to take part in a research project that will be conducted at University Hospitals Birmingham NHS 
Trust and Aston University. Before you decide if you wish to take part, it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the following information carefully. Please also 
take time to decide whether or not you wish to take part. If there is anything that is unclear or if you would like more 
information please do ask. Please feel free to discuss this information with others and thank you for reading. 
WHO IS DOING THE RESEARCH?  
This study is being conducted by a team based between the Queen Elizabeth Hospital, Birmingham and Aston University. 
This includes Professor Yusuf Rajabally, who is a Consultant Neurologist and Honorary Professor of Neurology at Aston 
University and Dr Andrew Lawley, who is a Specialist Registrar in Clinical Neurophysiology. 
WHAT IS THE PURPOSE OF THE STUDY? 
Fatigue is a common and often troubling symptom in nerve illnesses including Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP) and Charcot-Marie Tooth disease (CMT). However, it is currently unknown if fatigue might be 
related to loss of peripheral nerve cells in the arms and legs, or due to dysfunction of certain areas within the brain. Such 
information would help advance our understanding of what causes these symptoms. It could also help doctors to more 
accurately assess patients with these conditions who suffer from fatigue, and additionally may guide future research into 
different treatments for fatigue.  
We are therefore conducting this study to assess if there is any relation between fatigue and either peripheral nerve loss 
or with dysfunction in certain brain areas. We are also interested to discover what effect your current treatment is having 
in relation to fatigue. 
WHY HAVE I BEEN INVITED? 
You are being invited to take part in a research study investigating the reason for fatigue experienced by patients with 
nerve disorders. You have been chosen as you suffer from CIDP, CMT or another Acquired Nerve illness. 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
Before being given this information sheet you will have had an initial meeting with one of the research team who will have 
described the outline and purpose of the study. You will be invited back for a second meeting at Aston Brain Centre within 
the 4 days before your regular treatment at Queen Elizabeth Hospital (either immunoglobulin or physiotherapy). At this 
point you will have a chance to ask any further questions you may have and if you are happy to participate we will ask you 
for written consent to proceed. At any subsequent appointments as part of this study, you will have the opportunity to ask 
questions, and at any point you may withdraw consent and stop participation. If you refuse consent or withdraw from the 
study, this will have no impact whatsoever on your usual clinical care. 
As is common practice, your General Practitioner would be informed that you are participating in a research study and the 
reasons for this research study. 
During your visit to Aston Brain Centre at Aston University you will have: 
 
1. A full examination of your neurological system, which will assess your strength, sensation, reflexes, balance, 
coordination, gait (as at each one of your usual visits). As part of this examination, several questionnaires will be 
completed to evaluate fatigue, function, mood and quality of life. This should take around 45 minutes. 
2. A set of electrical tests (nerve conduction studies). During these tests, you may feel brief tingling sensations in your 
hands and legs, however these should not be painful.  A new simple technique called MUNIX will also record your 
voluntary muscle contractions. However, you will NOT at any stage have a needle (EMG) test. This should take up to 40 
minutes. 
 
Either on the same day, or on a separate visit within a few days, you will have the following test in the Aston Brain Centre 
at Aston University:  
 




3. A non-invasive imaging technique called functional Magnetic Resonance Imaging (fMRI). This will be performed by 
technicians experienced in performing this technique based at Aston University. This uses a magnetic field to produce 
high-quality brain images without the use of harmful radiation. During the scan, you will be asked to perform simple 
mental arithmetic. Once the scanning process begins there will be a loud "knocking" noise from the magnetic coils 
changing pulse direction. This is normal and you will be given ear plugs to keep the noise to a minimum.  This should 
take 60 minutes. You will be given a safety button during the MRI, which can be pressed to stop the test at anytime. 
 
Although these tests are completely non-invasive, widely used and very safe, there are some circumstances when you 
should not have them, for example, if you have any metal implanted in your body. At the start of the study we will check if 
there any reasons that you cannot undergo a test. If you have claustrophobia, you will not undergo the MRI part of the 
study. 
 
You will undergo these same steps again (1, 2 and 3), 10-15 days after immunoglobulin treatment if you have CIDP, or 3 to 
5 weeks after start of your physiotherapy programme (if you have CMT or another Acquired Nerve illness), with further 
visitation to the Aston Brain Centre at Aston University. All travel costs will be reimbursed at a standard rate of 40p/mile. 
 
DO I HAVE TO TAKE PART?  
Your participation is entirely voluntary and the care you receive will not be affected in any way by choosing not to. If you 
do decide to take part in the study you will be free to withdraw at any time and for any reason. If you chose to leave the 
study you can also choose to have your data removed if you notify the researcher by e-mail, telephone or in person. 
ARE THERE POSSIBLE BENEFITS OF TAKING PART?  
You will be given detailed feedback/information regarding your levels of fatigue and quality of life, through assessments 
which are not a part of routine clinical care. This may help you to monitor your response to your normal treatment. 
ARE THERE ANY DISADVANTAGES TO TAKING PART IN THE STUDY?  
Some of the tasks you will be asked to perform are designed to cause temporary fatigue. You may therefore 
temporarily feel more tired than usual after the test for a short time. There are no other disadvantages to taking 
part in this study. The assessments used, including the physical examination, electrical nerve and MRI testing 
are all extremely safe and very commonly used in routine clinical care. You will not receive any new treatments as 
part of this study. 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL?  
Your participation in this study will be kept confidential, and all data will be handled in accordance with the Data 
Protection Act. During the study all paper records of your results will be stored in a secure location at Aston University and 
labelled with a unique patient identification code known only to the research team. 
At the end of the study, the consent forms, study documentation and research data will be sent to Aston University for 
archiving. All data will be stored in a secure location at Aston University for a maximum of 6 years.  The research data will 
be anonymised (i.e. no one will be able to link you to your results). 
Information collected at each study visit will be used only for the purposes of the research outlined earlier in this 
information sheet. In the unlikely event that your MRI scan detects an unexpected finding, this will be reviewed by a 
Consultant who will decide if the scan needs to be looked at by a Radiologist. Any unexpected findings will be 
communicated to you by the research team. If you require further investigation or treatment, we may then ask your GP to 
refer you to an appropriate medical professional. 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY?  
The results will be written into a study report, and may also be published in a medical journal and/or presented at a 
medical conference. All data included in any report will be strictly anonymous, meaning anybody reading or listening to the 
report would be unable to identify you. None of your personal information would be included in the study report. If you 
wish to obtain a summary of the research findings please leave your contact details with the researchers and these will be 
sent to you. 
WHO HAS REVIEWED THE STUDY?  
This study has been reviewed and given a favourable opinion by the NHS Health Research Authority, whose role is to 
ensure that all research undertaken in England protects and promotes the interests of patients. 
WHAT IF THERE IS A PROBLEM? 




If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to 
answer your questions (contact details below). If you have any questions regarding your rights as a research participant or 
complaints about the way the study has been conducted, please contact the Secretary of the Aston University Research 
Ethics Committee:  Aston University, Aston Triangle, Birmingham, B4 7ET; : 
 
WHERE CAN I FIND INDEPENDENT INFORMATION ABOUT TAKING PART IN RESEARCH?  
You can contact the NHS Patient Advisory Liaison Service (PALS) University Hospitals Birmingham NHS Trust if you would 
like advice on taking part in research. Email: PALS@uhb.nhs.uk or Telephone:  
WHAT HAPPENS NEXT?  
You will be contacted by a member of the research team and invited for a further meeting to confirm if you wish to take 
part in this study. 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Chief investigator Prof Yusuf Rajabally 
Neurology department, 






Researcher Dr Andrew Lawley 
Clinical Neurophysiology department, 






Thank you for taking time to read this information sheet. 
 
  




Appendix 3: Study consent form 
Study Number: 162-2016-YR 
Participant Identification Number: 
Chief Investigator: Prof Y Rajabally 
CONSENT FORM 
Title of Project: Fatigue in Neuropathic Disorders (FIND) Study    Please initial 
box  
1. I confirm that I have read the information sheet dated 18/05/17 (version 6) for the 
above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected during 
the study, may be looked at by the study sponsor, individuals from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records.  
 
4. I understand that the information collected about me will be used to support 
other research in the future, and may be shared anonymously with other researchers. 
 
5. I agree to my General Practitioner being informed of my participation in the study and informed of 
any unexpected finding that may need further investigation. 
 
6. I confirm that I have understood what is involved in the MRI scan. 
 
7. I agree to take part in the above study. 
 
            
Name of Participant  Date    Signature 
 
            
Name of Person  Date    Signature 
taking consent 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes. 
  




Appendix 4: GP information sheet 








Dear Dr  
Re: Your patient 
Study title: Fatigue in Neuropathic Disorders (FIND Study). 
 
Your patient has recently agreed to participate in the above study which is taking place at the Aston 
Brain Centre, Aston University.  This is a non-interventional study and no further action is required 
from yourself. This letter is for information only. 
Details of the study are outlined in the enclosed patient information sheet. Information collected as 
part of this study will be used for research purposes only. However, part of this study uses fMRI and it 
is possible an unexpected finding may be detected requiring further investigation or treatment. In this 
unlikely event, you may be contacted by one of the research team to request assistance referring the 
patient to an appropriate specialist or for further investigation. 
If you require any further information please do not hesitate to contact me on the above number, or 




Yusuf A. Rajabally, 












Appendix 5: Electrophysiological studies in patients with CIDP and CMT 
Motor nerve conduction studies were performed in 4 nerves unilaterally (median, ulnar, peroneal 
and tibial), with averaged values for each patient calculated from all the nerves from which 
responses could be recorded. Motor conduction velocities were calculated from distal nerve 
segments. Proximal-evoked potential refers to the most proximal point from which a CMAP could be 
elicited (excluding Erb’s point due to concerns regarding submaximal nerve stimulation). Sensory 
nerve conduction studies were performed in 4 nerves unilaterally (sural, median, ulnar and 
superficial radial), with averaged values calculated in the same way. Values are presented as median 
values (IQR). Only parameters that could be recorded in at least 10 patients are presented (F-waves 
were only present in 7 of the 15 CMT patients). 
 CIDP CMT 
DML (ms) 5.7 (4.7-6.8) 8.6 (8.1-10.7) 
dCMAP amplitude (mV) 5.4 (2.7-5.9) 4.0 (3.1-4.4) 
dCMAP area (mV*ms) 14.9 (8.6-17.7) 14.0 (11.4-16.5) 
dCMAP duration (ms) 7.3 (6.0-8.9) 7.7 (7.0-10.0) 
pCMAP amplitude (mV) 3.4 (1.6-4.7) 2.3 (1.7-3.3) 
pCMAP area (mV*ms) 11.3 (5.4-17.0) 8.9 (7.7-12.7) 
pCMAP duration (ms) 7.7 (6.8-10.2) 9.2 (8.2-12.7) 
Motor NCV (m/s) 38.9 (33.0-43.1) 19.9 (17.9-20.7) 
F-wave latency (ms) 41.0 (39.2-49.0) - 
F-wave persistence (%) 56.7 (38.3-74.2) - 
   
SNAP amplitude (µV) 4.7 (3.2-7.1) 5.6 (2.6-5.9) 
Sensory NCV (m/s) 42.5 (37.9-45.9) 21.6 (17.7-28.1) 
 
  




Appendix 6: Correlation analysis between electrophysiological parameters and clinical 
assessments 
Tables demonstrating correlation analysis between electrophysiological parameters and clinical 
assessments in patients with CIDP (first table) and CMT (second table). Motor nerve conduction 
studies were performed in 4 nerves unilaterally (median, ulnar, peroneal and tibial), with averaged 
values for each patient calculated from all the nerves from which responses could be recorded. 
Sensory nerve conduction studies were performed in 4 nerves unilaterally (sural, median, ulnar and 
superficial radial), with averaged values calculated in the same way. Correlation analysis was 
performed using Spearman Rank correlation. Results are presented as r values (95% confidence 
intervals). Significant correlations (p<0.05) are highlighted in bold.  
CIDP patients (n=26) 
























































































































































        

































CMT patients (n=14,  1 patient did not tolerate NCS) 




























































































































F-wave latency - - - - - - - 
F-wave persistence - - - - - - - 
        




































Appendix 7: Final version of manuscript submitted for publication in Clinical 
Neurophysiology journal 
doi: 10.1016/j.clinph.2019.06.231 
Motor unit number index (MUNIX) in chronic inflammatory 
demyelinating polyneuropathy: a potential role in monitoring 
response to intravenous immunoglobulins 
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